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Abstract
The process to develop a guideline in a European setting remains a challenge. The ESCMID Fungal Infection Study Group (EFISG) success-
fully achieved this endeavour. After two face-to-face meetings, numerous telephone conferences, and email correspondence, an ESCMID
task force (basically composed of members of the Society’s Fungal Infection Study Group, EFISG) finalized the ESCMID diagnostic and man-
agement/therapeutic guideline for Candida diseases. By appreciating various patient populations at risk for Candida diseases, four subgroups
were predefined, mainly ICU patients, paediatric, HIV/AIDS and patients with malignancies including haematopoietic stem cell transplanta-
tion. Besides treatment recommendations, the ESCMID guidelines provide guidance for diagnostic procedures. For the guidelines, questions
were formulated to phrase the intention of a given recommendation, for example, outcome. The recommendation was the clinical interven-
tion, which was graded by a score of A–D for the ‘Strength of a recommendation’. The ‘level of evidence’ received a score of I–III. The
author panel was approved by ESCMID, European Organisation for Research and Treatment of Cancer, European Group for Blood and
Marrow Transplantation, European Society of Intensive Care Medicine and the European Confederation of Medical Mycology. The guide-
lines followed the framework of GRADE and Appraisal of Guidelines, Research, and Evaluation. The drafted guideline was presented at
ECCMID 2011 and points of discussion occurring during that meeting were incorporated into the manuscripts. These ESCMID guidelines
for the diagnosis and management of Candida diseases provide guidance for clinicians in their daily decision-making process.
Keywords: Candida, Europe, framework, guideline development, recommendation
Clin Microbiol Infect 2012; 18 (Suppl. 7): 1–8
Corresponding author: A. J. Ullmann, Infectious Diseases, Department of Internal Medicine II, Julius-Maximilians-University, Oberdu¨rrbacher Str. 6,
97080 Wu¨rzburg, Germany
E-mail: andrew.ullmann@uni-wuerzburg.de
Information in this manuscript was presented in part at ECCMID 2011.
*European Society for Clinical Microbiology and Infectious Diseases
Members of the subgroup committee mainly responsible for this manuscript.
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ESCMID PUBLICATIONS 10.1111/1469-0691.12037
Introduction
Preparing guidelines in this day and age can be likened to the
quest of the search for the Holy Grail. Numerous guidelines
have been published in a variety of countries and by different
scientific societies. All have the common goal of proving clini-
cians with best guidance for their daily working environment.
Obviously, there is no single pathway to the truth in the field of
medicine because science and the art of medicine are in a con-
stant state of flux, published data might have already become
obsolete and its interpretation might be biased unwittingly.
Nevertheless, it was apparent that certain guidelines for
Europe are missing. Firstly, the majority of guidelines focus on
treatment, usually only one host group at risk, and to a far les-
ser extent only a few focus on diagnostic procedures [1–10].
Moreover, North American guidelines are frequently cited in
the literature, and this demonstrates their clear dominance
[11–15]. Hence, recommendations for diagnostic procedures
provided a clear impetus to our group of microbiologists,
pathologists, haematologists and infectious diseases physicians
(some with dual or more qualifications). In addition, differ-
ences in epidemiology by geography, age and local factors
needed some attention. Our aim was to provide comprehen-
sive European guidelines focusing on a single fungal disease
entity caused by a single genus, namely Candida species to
allow comprehensive coverage of diagnostics and treatment,
recognizing that not all patient risk are alike. It became obvious
very quickly that a matrix was needed to cover all topics of
interest. This needed to be considered during the guidelines
preparation. The guidelines are published as a supplement to
CMI and aim to provide greater awareness and better insights
into Candida diseases for the clinicians.
It was decided that the guidelines for the diagnosis and
management of Candida diseases is divided into five separate
parts, each of which can be used as stand-alone recommen-
dations of the ESCMID treatment management guideline for
each risk group of patients and diagnostic procedures.
Methods
Author panel recruitment and organization
The development of any guideline requires certain steps to
ensure the production of an unbiased, independent and high-
quality document. The executive board of EFISG decided to
proceed first with a guideline for Candida diseases. The
members of the EFISG group were first asked if they wanted
to participate. Participants were chosen on the basis of their
expertise in the field of medical mycology and in particular
Candida disease, and further had experience in generating
guidelines (Fig. 1). Contact was made through the ESCMID
Executive Committee with four different European scientific
societies. European Group for Blood and Marrow Transplan-
tation (EBMT), European Confederation of Medical Mycology
(ECMM), European Organisation for Research and Treat-
ment of Cancer (EORTC) and European Society of Intensive
Care Medicine (ESICM) approved the list of experts and
made additional suggestions for experts. Some of the nomi-
nees are also members of the ESCMID and were included
into the group as panel authors. Experts who were not
FIG. 1. Working modules and experts participating in the development of the guidelines (susceptibility testing is included for the diagnostic pro-
cedures).
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selected were asked to peer review the guideline to ensure
further quality, although the final decision for the choice of
peer reviewers rested with the Editor-in-Chief of CMI.
These expert reviewers from the European scientific socie-
ties are acknowledged in this paper. This is a novel proce-
dure because reviewers are usually not explicitly mentioned
in terms of which papers they have reviewed.
Obviously, to achieve its aim, to provide a European
guideline, the group needed to balance between different
geographical regions of Europe. The list of representatives of
the various European countries is provided in Table 1. For
further proficiency, a group coordinator of each subgroup
was nominated to provide and present the results of the dis-
cussion of this subgroup to the plenary sessions. The sub-
groups were set up by EFISG. They searched for relevant
literature (by PubMed). This literature database was made
available to the whole panel on an ftp server of ESCMID.
During 2010–2012, documents and views were shared by
email, teleconferences and face-to-face meetings. Once a first
consensus was reached, the preliminary recommendations
were presented to the whole group, that is, the other
authors, and subject to wide discussion, developed further,
and finalized as a group consensus. Two weekend meetings
took place in 2010 and 2011 to finalize the guidelines. The
finished guidelines were presented during a workshop ses-
sion at the ECCMID 2011, and points of discussion occurring
during that meeting were incorporated into the final publi-
cized manuscripts. The organization plan used for the guide-
line is provided in Fig. 2.
Intention of the recommendation with defined intervention
During the preparation process, new ideas were incorpo-
rated to provide best clinical guidance. Pragmatic questions
arising in everyday patient care needed to be addressed
appropriately. For this reason, the ‘intention’ for a recom-
mendation was defined beforehand and framed in terms of
‘What does the clinician want?’ and a response was tailored
to address the different aspects of a given Candida disease.
Obviously, the diagnostic and therapeutic intervention that
TABLE 1. List of the representatives associated with the
country
Country Number
(ID)
Number (CM and
diagnostic experts)
Total
number
Austria 0 1 1
Belgium 1 0 1
Denmark 0 1 + 1a 2
France 1 + 1b 0 2
Germany 3c 0 3
Greece 2 0 2
Italy 3 0 3
Netherlands 1 2 3
Spain 0 1 1
Switzerland 2 1d 3
Turkey 1 1d 2
United Kingdom 1 1 2
ID, infectious diseases specialist; CM, clinical microbiologist.
aPathologist.
bHaematologist.
cDual trained in ID and haematology.
dDual trained in ID and CM.
FIG. 2. Organization plan of the guidelines.
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had the greatest impact on survival of the patient was given
the highest priority in terms of a recommendation.
Certain recommendations were originally controversial.
Guidelines are no consensus meeting, but nevertheless, a
majority vote was a necessity to formulate a recommenda-
tion if a major disagreement occurred. Only a few of the dis-
cussions were intense but only had one common goal in
mind—to provide the best option for diagnosis and therapy.
But whatever the decision, it was one we ensured to be the
best for patients.
Every recommendation within the guidelines attempts to
indicate clearly the intention (e.g. improved survival) and to
describe the diagnostic or therapeutic option (intervention).
Therefore, the guidelines follow the principles of the ‘Grades
of Recommendations, Assessment, Development, and Evalua-
tion’ (GRADE) [16]. For every recommendation, the follow-
ing three questions were considered:
1 What do clinicians want (outcomes)? What is their inten-
tion?
2 Which option is better for patients? What intervention is
needed to reach the desired outcome?
3 Review the chosen option whether it is truly better or
not by adequate review of the literature.
These guidelines also adopted the ‘Appraisal of Guidelines,
Research and Evaluation’ (AGREE) items for the development
of guidelines as well [17,18] and basically all domains of AGREE
were addressed:
1 Scope and purpose, for example, clinical questions cov-
ered by the guideline is described.
2 Stakeholder involvement, for example, the patient’s view
and preferences have been sought.
3 Rigours of development, for example, the health-related
benefits, side effects and risks have been considered in
formulating the recommendations.
4 Clarity of presentation, for example, key recommenda-
tions are easily identifiable, i.e. tables.
5 Applications, for example, the potential cost-related
implications of applying the recommendations have been
considered.
6 Editorial independence, for example, the guideline is edi-
torially independent from the funding body.
Within the guideline, questions were formulated and
answered according to their clinical importance. Because the
guideline author panel appreciated that not all patients were
alike, various risk groups were defined according to risk and
handled accordingly, that is, patients with HIV/AIDS, those in
the ICU, transplant recipients, haematological malignancies
and cancer and paediatric populations. At all times, the
patient’s view and preferences were kept to the fore. One
good example that caused some heated debates was the rec-
ommendation of not administrating amphotericin B deoxych-
olate to adults. This drug formulation with considerable
toxicity, morbidity and mortality issues, but in regard to
acquisition costs relatively cheap has better alternatives at
least in Europe available albeit at greater costs. The responsi-
bility to ensure good medical help needed to be considered,
and the follow-up costs for the numerous side effects would
make the choice of a less cheaper drug acceptable [19]. The
ethical dilemma although is obvious but on balance, it was
felt that given the facts, the choice of a more expensive for-
mulation was acceptable.
Strength of recommendation
Numerous grading systems of recommendations exist, and it
is imperative that they should be not too complicated to
understand for the user. Hence, we utilized a similar system
as previously employed by the Canadian Task Force of the
Periodic Health Examination and the IDSA [12,20]. This is a
four-category grading system for the ‘strength of a recommen-
dation’. Two extreme ends of the grading system were impor-
tant: (A) ESCMID strongly supports a recommendation for
use and on the other side: (D) ESCMID recommends against
the use. This differentiation was important to clearly define
treatment management for or against the use of a given inter-
ventions. The grade C is weighted with the evidence available
and could be considered optional (Table 2). The grading of
the ‘strength of a recommendation’ can be compared to traf-
fic lights, with green indicating the recommendation for use
and red the recommendation against use.
The ‘strength of a recommendation’ cannot easily be
applied to diagnostic recommendations. Therefore, an alter-
TABLE 2. Strength of the ESCMID recommendation and
quality of evidence
*
*
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native system was adopted for biomarkers (non-cultural
techniques), which included test accuracy, as this plays a
pivotal role in providing an appropriate diagnosis. The
GRADE system was used to grade the ‘strength of a rec-
ommendation’ and ‘quality of evidence’ [21,22]. Therefore,
the system was slightly modified and is applicable for bio-
markers (non-cultural techniques) only. The term accuracy
of a test was introduced, and a grading system was imple-
mented on those calculated numbers (Table 3). The grading
system used a clear statement, that is, highly recommended,
recommended and not recommended and did not utilize
the alphabet system for treatment. If no published data
were available to support any kind of recommendation, no
recommendation for the test was provided. The equation
for accuracy was the sum of true positive and true negative
tests divided by the sum of all tests performed. The word-
ing for the ‘quality of evidence’ was changed only marginally
to maintain a streamlined recommendation grading system
(Table 3).
Quality of evidence
The ‘strength of a recommendation’ was largely based on
the available studies and publications. Although there were
obvious exceptions, for example, drawing blood cultures for
candidaemia because in this case, no literature was cited. On
the other hand, various publications discussed issues sur-
rounding the selection of appropriate literature [23,24]. This
literature should support the judgement made by the panel.
This guideline is not a classical systematic review of the liter-
ature. It was clearly intended to review the literature on the
impact of the test and alternative management strategies
on the outcome in patients [25]. The panel reviewed
the available evidence and recognized its limitations but
interpretation bias cannot be ruled out entirely. The panel
always kept its focus on the need for an evidence-based
(medicine) justification. Despite some limitations in the selec-
tion process, by which means every subgroup was internally
responsible for, all retrieved literature (by PubMed) were
considered. A meta-analysis was not intended and not all
retrieved literature was cited. Nevertheless, we rated the
evidence as the Canadian Task Force on the Periodic Health
Examination and the IDSA [12,20]. One modification was
added to the level II of ‘Quality of Evidence’. The panel rec-
ognized that not all questions could be answered by pub-
lished literature but, for example, similar immunological
situations or a substantial abstract from larger international
recognized scientific meetings could be used as ‘evidence’.
Therefore, especially for academic purposes and to increase
transparency, indices were added to the level II of ‘Quality
of Evidence’ (Table 1).
Discussion and conclusions
These ESCMID guidelines provide a European-wide guideline
for clinical guidance in the diagnosis and treatment of Candida
diseases. The guidelines offer besides diagnostic also treatment
recommendations for various patients’ groups and are
weighted differently according to available literature. The basis
of these guidelines were to follow the framework provided by
GRADE and AGREE [16–18,24–26]. The panel fully acknowl-
edges numerous published guidelines and recognized some
shortcomings that the ESCMID guideline tried to overcome:
Mainly providing an independent European guideline for diag-
nostic procedures and treatment recommendations suitable
for all patients at risk for Candida diseases. Obviously, not all
patient profiles are homogeneous, as their risk profile and
response to therapy may differ. Minor changes in the view of
rating systems were implemented into this guideline.
These guideline should also serve as a tool for guiding the
clinical care of patients in Europe. The ESCMID guidelines
consist of text but also includes tables that are easily read-
able. The development of the guidelines was made transpar-
ent, and the panel was also supported by other European
societies as well as a broad panel of experts from various
backgrounds and countries. The guidelines were (peer-)
reviewed by other experts in the field of medical mycology
and who were in part suggested by other European societies.
Their pivotal role by peer review in the process of the
guideline development cannot be underestimated and the
entire panel expresses their gratitude by acknowledging their
work at the end of this manuscript.
TABLE 3. System used in these guidelines for grading
quality of evidence about the accuracy of biomarker
detection procedures in the diagnosis of candidiasis
Accuracya
Highly recommended Technique is accurate in >70% of cases (most)
Recommended Technique is accurate in 50–70% of cases
(reasonable number)
Not recommended Technique is accurate in <50% of cases (small number)
No recommendation No data
Quality of evidence accepted
Level I Evidence from at least one properly designed
prospective multicentre cross-sectional or
cohort study
Level II Evidence from
(1) at least one well-designed prospective single-centre
cross-sectional or cohort study or
(2) a properly designed retrospective multicentre
cross-sectional or cohort study or
(3) from case–control studies
Level III Opinions of respected authorities, clinical experience,
descriptive case studies, or reports of expert
committees
aAccuracy was defined as: (Numbers of true positives + true negatives) divided
by (Numbers of true positives + false positives + false negatives + true negatives).
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The development of guidelines comes with a price tag, as
there are inevitably costs incurred by travel and accommoda-
tion. Funding was neither sought nor granted by biomedical
or pharmaceutical companies for the development of these
guidelines. Additionally, biomedical or pharmaceutical compa-
nies were not involved in the development of these guide-
lines neither as observers or discussants. For this reason, we
received a grant of 50 000€ from ESCMID to accomplish this
task. Transparency declarations of the panel are provided to
every guideline. This support by ESCMID guaranteed inde-
pendence including editorial independence.
Challenges remain for the guidelines. Trying to assess Can-
dida epidemiology in Europe remained a challenge because
only a few adequate European publications were available.
The guidelines want to serve as a tool for guidance as for
local (hospital) guidelines, which would require individual
adaptations to meet local needs [27]. Therefore, it remains
important to have European guidelines that can be adapted
to local use.
Costs incurred by diagnostic procedures or treatments are
not considered mainly because of the differences of reim-
bursement systems in Europe. Cost effectiveness calculations
of different treatment modalities have been assessed by others
but are only applicable for the specific countries (e.g. [28]).
Obviously, more research is needed in the field of Candida
diseases particular in epidemiology and the development of
resistance. ‘Strength of a recommendation’ with a grading of
‘C’ highlights our obligation to further work in this area to
arrive at a more adequate or satisfactory answer. The EFISG
is actively developing guidelines in other fields of medical
mycology (e.g. rare and emerging fungi and aspergillosis) and
will seek cooperation with other scientific societies sharing
this goal. The current Candida guidelines are planned to be
reviewed in the next 5 years to ensure it remains up to date.
If new and pivotal clinical data become available, then the
planned update will take place earlier.
In summary, these ESCMID guidelines are independent of
any industry funding or support or influence and were
drafted as an independent recommendation by 25 European
experts from 12 countries. The panel of authors hopes that
these ESCMID guidelines for the diagnosis and management
of Candida diseases will provide adequate guidance for
clinicians in everyday decision-making process, which can be
easily adapted to their clinical practice.
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Introduction
One of the main novelties of the ESCMID Candida Guidelines
is the inclusion of recommendations about diagnostic proce-
dures. The aim of these guidelines is to appraise the different
techniques and procedures for detection and investigation of
Candida infections. Timing of antifungal therapy has been
shown to have major impact on hospital mortality. As the
mortality associated with invasive Candida infections remains
high, it is important to make optimal use of diagnostic tools
to initiate antifungal therapy as early as possible with the
best antifungal drug. In addition to diagnostic tools under-
standing of the local epidemiology, patient risk factors and
resistance profiles of Candida species are essential. In some
geographical areas, the number of patients with candidiasis is
rising associated with an increase in the number of patients
with immunosuppression and the expanding utilization of
intensive care units. New diagnostic utilities are being imple-
mented. Most of the new detection methods have been
designed to diagnose invasive candidiasis and have been
shown to be valuable techniques, which could detect infec-
tion early.
This article includes recommendations about conventional
methods of microbiological diagnosis of deep-seated, oropha-
ryngeal, oesophageal and vaginal candidiasis, antifungal sus-
ceptibility testing (AST) and alternative diagnostic procedures
also known as nonculture, biomarker detection procedures.
Some issues about therapeutic drug monitoring (TDM) of
antifungal agents are also commented upon.
Clinicians often use diagnostic tests as a package or strat-
egy based on evidence regarding the accuracy of procedures.
Several proposals have been published for grading quality of
evidence and strength of recommendations for diagnostic
tests and strategies [1]. Although recommendations on diag-
nosis share the fundamental logic of recommendations for
other interventions, they present unique aspects. Conven-
tional diagnostic procedures such as microscopical examina-
tion, culture and identification of microorganisms are
essential investigations, and their performance depends on
the possibility of obtaining samples of deep tissues. Conse-
quently, grading the quality of evidence and strength of rec-
ommendation for conventional methods of diagnosing
candidiasis has not been included in this guideline.
However, strengths of recommendations about new non-
culture-based techniques for biomarker detection can be
assigned because many techniques are available showing dif-
ferent levels of accuracy. The use of tests to establish the
presence or absence of the disease and their utility as early
diagnostic methods can be also evaluated. Table 1 shows the
system used in these guidelines for grading quality of evi-
dence about the accuracy of biomarker detection procedures
in the diagnosis of candidiasis.
This document was written by a panel of experts of the
European Fungal Infection Study Group (EFISG) of the ESC-
MID. The text is divided into seven sections, and the object
of the experts was to draw up a series of practical recom-
mendations, with the aim of answering all the questions faced
by health professionals when designing diagnostic strategies
for detecting Candida infections.
1. What are the best tests for diagnosing
candidaemia?
Candidaemia can be defined as the presence of any species
of the genus Candida in the blood. Subsequently, blood cul-
tures (BC) are essential for diagnosing candidaemia [2].
There are a number of international guidelines including gen-
eral recommendations for taking and processing of blood
samples to ensure the optimal isolation of microorganisms
[3–6].
The number of BC recommended in a single session is 3
(2–4), with a total volume varying according to the age of
the patient, 40–60 mL for adults, 2–4 mL for children under
2 kg, 6 mL between 2 and 12 kg, and 20 mL between 12 and
36 kg. The timing for obtaining the BC is one right after the
other from different sites, and venipuncture remains the
technique of choice. A BC set comprises of 60 mL blood for
adults obtained in a single session within a 30-min period
and divided in 10-mL aliquots among three aerobic and three
TABLE 1. System used in these guidelines for grading
quality of evidence about the accuracy of biomarker
detection procedures in the diagnosis of candidiasis (based
on reference 1)
Accuracya
Highly recommended Technique is accurate in >70% of cases (most)
Recommended Technique is accurate in 50–70% of cases
(reasonable number)
Not Recommended Technique is accurate in <50% of cases (small number)
No recommendation No data
Quality of evidence accepted
Level I Evidence from at least one properly designed
prospective multicentre cross-sectional or
cohort study
Level II Evidence from (i) at least one well-designed
prospective single-centre cross-sectional or
cohort study or (ii) a properly designed
retrospective multicentre cross-sectional or
cohort study or (iii) from case-control studies
Level III Opinions of respected authorities, clinical experience,
descriptive case studies or reports of expert
committees
aAccuracy was defined as: (Numbers of true positives + true negatives) divided by
(Numbers of true positives + false positives + false negatives + true negatives).
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anaerobic bottles. The frequency recommended is daily when
candidaemia is suspected, and the incubation period must be
at least 5 days.
When these recommendations have been followed the
sensitivity of BC to detect Candida is 50–75% although lower
sensitivity rates in neutropenic patients and those undergoing
antifungal treatment have been reported [7,8]. Some other
remarks should be noted. Sensitivity varies depending on the
species and system used. For instance, C. glabrata grows less
optimally in the BACTECTM medium (Becton Dickinson
Diagnostic Systems) unless a mycosis bottle is included [7,8].
Identification to species level is mandatory because antifungal
therapy can vary according to Candida species. In addition,
yeasts in BC are not always Candida as other emerging and
rare yeast pathogens have been involved in up to 5% of
patients with fungemia. Lysis-centrifugation procedures
showed higher efficacy when older BC systems were used as
comparators. The recommendation of the panel was to use
an automated validated BC system.
The performance of BC is not very high, and they cannot
be considered as early diagnostic techniques. Alternative
procedures based on the detection and quantification of fun-
gal biomarkers and metabolites have been developed to
improve and anticipate the detection of candidaemia. Table 2
includes the recommendations of the panel about the clinical
use of these techniques.
The combined detection of mannan and anti-mannan anti-
bodies is considered to be a method for specific detection of
Candida spp. in serum samples [9]. There is a combination of
tests available [Platelia Candida Antigen Plus (Ag PlusTM) and
Antibody Plus (Ab PlusTM; Bio-Rad Laboratories)]. A number
of studies, based on previous generations of these tests,
reporting evidences from properly designed retrospective
multicentre cross-sectional or cohort study and from case–
control studies have proven their efficacy in the diagnosis of
candidemia, with sensitivity and specificity rates around 80%
and 85%, respectively, which translates into an accuracy of
50–70%. Serial determinations may be necessary. These
assays can help to detect the infection early because they
can be positive 6 days on average prior blood cultures. It
shows also very high negative predictive value (>85%) and
can be used to rule out infection. The panel considered the
method as recommended for the diagnosis of candidaemia. It
could be used as part of a diagnostic strategy to establish
TABLE 2. Summary of recommendations by Candida disease, specimen and test evaluated
Disease Specimen Test Recommendation Level of evidence
Candidaemia Blood Blood culture Essential investigationa NA
Serum Mannan/anti-mannan Recommended II
B-D-glucan Recommended II
Other antibodies No recommendation No data
Septifast PCR kit No recommendation No data
In-house PCR No recommendation No data
Invasive candidiasis Blood Blood culture Essential investigation NA
Serum Mannan/anti-mannan No recommendation No data
B-D-glucan Recommended II
Septifast PCR kit No recommendation No data
In-house PCR No recommendation No data
Tissue and sterile body fluids Direct microscopy and histopathology Essential investigation NA
Culture Essential investigation NA
Immuno-histochemistry No recommendation No data
Tissue PCR No recommendation No data
In situ hybridization No recommendation No data
Chronic disseminated
candidiasis
Blood Blood culture Essential investigation NA
Serum Mannan/anti-mannan Recommended II
B-D-glucan Recommended II
Septifast PCR kit No recommendation No data
In-house PCR No recommendation No data
Tissue and sterile body fluids Direct microscopy and histopathology Essential investigation NA
Culture Essential investigation NA
Immuno-histochemistry No recommendation No data
Tissue PCR No recommendation No data
In situ hybridization No recommendation No data
Oropharyngeal and
oesophagic candidiasis
Swab Culture Essential investigation NA
In-house PCR No recommendation No data
Biopsyb Direct microscopy and histopathology Essential investigation NA
Culture Essential investigation NA
In-house PCR No recommendation No data
Vaginal candidiasis Swab/vaginal secretions Direct microscopy Essential investigation NA
Culture Essential investigation NA
Commercial tests Use validated test only NA
In-house PCR No recommendation No data
NA, not applicable.
aEssential investigation means it must be done if possible.
bOropharyngeal biopsy is not mandatory.
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the absence of the disease to reduce the unwarranted use of
antifungal agents in prophylactic and empirical regimens in
critical care settings (ICU).
The b-1,3-D-glucan detection (BDG) is also a technique
useful for Candida detection. It is not specific for Candida
because it is present in many fungal species. The BDG test is
considered to be a panfungal diagnostic method and was
included in the EORTC/MSG (European Organization for
Research and Treatment of Cancer/Mycosis Study Group)
diagnostic criteria for invasive fungal infections in 2008, for
all types of patients. There are several techniques on the
market for the detection of glucan in serum. In Europe and
America, the most used is Fungitell (Associated of Cape
Cod, Inc.). A number of meta-analyses have been undertaken
using data from cross-sectional, cohort and case–control
studies on the diagnosis of candidaemia. The sensitivity of
glucan detection was >65% in most studies with a cut-off
value of 80 pg/mL, with specificity rates >80%, positive likeli-
hood ratios approximately of 4, negative likelihood ratios of
0.50 and negative predictive values >85%. The use of albu-
min, gauzes, immunoglobulins or haemodialysis was associ-
ated with false positives, and the test seemed of greater
utility in patients who did not have haematological diseases
such as surgical or medical ICU patients suffering from Can-
dida infections [10]. The panel considered the BDG test
(FungitellTM only so far) as recommended for candidemia
detection in adults being also very useful for ruling out infec-
tion. Serial determinations (twice a week) are recommended.
The test has not been validated in children.
Regarding other alternative methods, the panel did not
make any recommendations because no data are available to
evaluate their utility for the clinical diagnosis of candidaemia.
Antibody detection kits such as Serion Elisa Classic and Can-
dida germ tube antibodies are under evaluation, and there are
limited data about their clinical accuracy. Molecular detection
techniques largely PCR-based have also been designed, and
several studies about their reliability are in progress. The
Light Cycler SeptiFast system (Roche) is a PCR-based com-
mercial kit to detect bacteria and fungi in blood samples.
Studies have reported some cases of candidaemia being
detected by this kit, but the number of cases is rather limited
and no recommendation can be made [11–13]. Regarding in-
house PCR techniques, many reports have been published
including more than 1000 patients [14–17]. Their pooled sen-
sitivity and specificity was calculated over 85% in a meta-anal-
ysis published recently [18]. None of the PCR techniques
included external validation and different material and meth-
ods were used. Third-party appraisal of results and harmoni-
zation of PCR-based techniques should be made before
recommendations can be made regarding clinical utility.
2. What are the best tests for diagnosing
invasive candidiasis?
Invasive candidiasis (IC) can be defined as a deep-seated dis-
ease, frequently a multiorgan infection including candidaemia
although BCs are negative in as many as one-third of the
cases at least in the ICU population [19]. Remarks about BC
were made in the previous section. This section relates the
recommendation by the panel about IC diagnosis using other
specimens and procedures.
Classical diagnostic methods, such as direct microscopy,
histopathology and culture, exhibit a limited sensitivity to
detect IC, and their usefulness depends on the possibility of
obtaining samples of deep tissues which, in many cases, can-
not be taken due to the patient’s condition. Therefore, these
approaches must be considered as essential investigations to
be performed if possible [3,5,6,20].
A number of considerations and recommendations were
highlighted by the panel about the classical methods.
Regarding tissue samples and body fluids from normally
sterile sites, they must be obtained and collected aseptically
and transported to the laboratory promptly. Small samples
are prone to sampling error. Tissue for histopathology
should be placed in fixative as rapidly as possible, and
microscopy should include special stains such as silver
stains and PAS. The use of optical brighteners is recom-
mended for microscopical examination of un-fixed speci-
mens. Microscopic examination requires expertise for
interpretation, and morphology cannot be used for defini-
tive identification [21–23].
Samples for culture should not be placed in histopathology
fixatives and must be kept moist. They have to be processed
promptly to avoid multiplication of organisms. If not possible,
storage at 4–5C is recommended. Fungal selective media
must be included, and it should be observed that some spe-
cies take several days (5–14 days) to grow in culture. Yeast
isolation from normally sterile tissues or fluids is usually
indicative of deep-seated infection. Negative culture results
do not exclude Candida infection. Identification of the isolate
to species level is mandatory [24,25].
Samples from tissues and body fluids can be also investi-
gated using alternative procedures. Among these, immuno-
histochemistry [21–23], in situ hybridization [26] and analysis
of samples by PCR-based procedures [15,27] have been posi-
tively evaluated in some studies, but they are not generally
available and third-party evaluation of their accuracy has not
been carried out so far. However, some general comments
can be made. PCR-based procedures must use free DNA
materials, and their performance may improve if they are
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carried out following laser microdissection [28]. Immunohis-
tochemistry has shown clinical utility to confirm infection
when yeasts have been seen in tissue and BCs were negative.
The panel recommended genus-specific antibody commer-
cially available only (e.g. Rabbit anti C. albicans, type A:Bio-
tin, Serotec, No. 1750-5557). It should be noted that only
positive results are reliable and negative results do not
exclude the disease. Regarding in situ hybridization and tissue
and body fluid PCR, there are no clinically validated commer-
cially available kits to detect fungal infections.
Detection of IC by quantification of fungal components in
body fluids other than serum has not been evaluated. However,
there are some reports including cases of IC and quantification
of serum biomarkers, but significant findings were reported for
the BDG test only [10]. According to these results, the BDG
test can be recommended for IC detection similar to that recom-
mendation made for candidaemia detection (Table 2).
3. What are the best tests for diagnosing
chronic disseminated candidiasis?
The same recommendations made for BC, tissue and body
fluid samples for the detection of IC (Table 2) can be consid-
ered for diagnosing chronic disseminated candidiasis (CDC).
The panel remarked, however, that a tissue biopsy is highly
advisable because CDC is rarely detected by BC. In addition,
the detection of biomarkers can be useful. As for IC, the
BDG test has shown to be strongly associated with clinical
findings and the panel considered the test as recommended
for CDC detection [10]. Chronic disseminated candidiasis
can be diagnosed by mannan and anti-mannan quantification.
A meta-analysis mentioned previously suggests that the tech-
nique is very useful in CDC cases [9]. The report included
21 cases of CDC and mannan and anti-mannan quantification
test exhibited 86% of sensitivity rate. Positive results were
seen 16 days in average prior to cultures.
4. What are the best tests for
oropharyngeal candidiasis and oesophagitis?
The essential specimen for the detection of those diseases is
a swab taken from the lesion. A biopsy is not mandatory
(Table 2), but it might discriminate between infection and col-
onization. Swabs must be inoculated on selective media to
avoid overgrowth by colonizing bacteria. Species identification
and susceptibility testing are recommended in recurrent/com-
plicated cases and in patients who have been exposed to az-
oles previously. When a biopsy is obtained, it must be
processed according to recommendations stated in the IC
diagnostic procedures section. PCR-based methods have been
evaluated, but no recommendation can be made as results
have not been validated in a clinical setting [5,29,30].
5. What are the best tests for Candida
vaginitis?
Examination of swabs and vaginal secretions is very valuable
in detecting this infection (Table 2). A swab is less useful for
microscopy than secretions. Vaginal secretions spread
directly onto a microscopy slide, and left to dry is recom-
mended. The observation of pseudohyphae can help to
detect the infection, but filaments can be observed in patient
without infection. In addition, not all Candida spp. form fila-
ments during infection (e.g. C. glabrata), and microscopy in
such cases will show only yeast cells [31].
Culture of swabs and vaginal secretions are also essential
investigations. Semi-quantitative techniques using fungal selec-
tive agar are recommended. Species identification and sus-
ceptibility testing are indicated in recurrent/complicated
cases and in patients with prior azole exposure.
Commercial tests designed to detect vaginal candidiasis
can be also used, but the panel recommended the use of val-
idated tests only [32,33]. PCR-based procedures have not
been validated, and no recommendations can be made [34].
6. When are AST recommended for
patient management and when for
epidemiological reasons?
Recommendations for AST were also made by the panel.
The panel considered that AST must be recommended for
patient management for all Candida strains isolated from
blood and other deep sites. Experts advised that reference
procedures [35–39] or validated commercial techniques
should be used [40–43]. However, it should be noted that
discrepant results may be obtained with commercial tech-
niques (such as EtestTM and Sensititre YeastOneTM) as com-
pared to the reference methods particularly for isolates with
borderline MIC values. Importantly, interpretation of AST
results requires expertise and cautious evaluation. It is essen-
tial to ensure the endpoints generated for each species mir-
rors those of reference methods before reference
breakpoints are adopted for interpretation of results by
commercial techniques. Antifungal susceptibility testing can
be useful particularly in some cases such as strains from
patients exposed to antifungal agents, isolates from patients
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with clinical failure, strains belonging to rare and emerging
species and species that are known to be resistant or less
susceptible to antifungal drugs [44,45].
Regarding superficial isolates, AST can be recommended for
patient management in cases who failed to respond to antifun-
gal agents or relapsing infection. Surveillance cultures from
patients exposed to antifungal agents could be also useful.
For epidemiological reasons, the panel recommended that
all isolates from blood and deep sites should be tested using
a reference method. Periodical epidemiological studies
should be carried out including strains isolated from superfi-
cial sites to determine the susceptibility profiles and resis-
tance rates for each individual centre [44,45].
Table 3 shows breakpoints to interpret AST results
approved by both the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) and the Clinical Laboratory
Standards Institute (CLSI) [46–53].
7. Is therapeutic drug monitoring indicated
for patient management?
The panel indicated that TDM must be used for patients
treated with 5-fluorocytosine. In addition, TDM is not nor-
mally required for drugs used (fluconazole, echinocandins
and amphotericin B formulations) in the treatment for Can-
dida infections except for patients with extra-corporeal
membrane oxygenation (ECMO) treated with echinocandins
as it can reduce the level of the antifungal being used [54–
57].
Therapeutic drug monitoring is recommended if vorico-
nazole or posaconazole is prescribed, and monitoring is
highly recommended in unsatisfactory response to therapy,
suspicion of toxicity or drug interaction(s), impaired liver or
renal function and also in patients on ECMO [58–60].
TABLE 3. Interpretative breakpoints of antifungal agents approved by EUCAST and CLSI for susceptibility testing of Candida
Antifungal Species
EUCAST CLSI
Susceptible Intermediate Resistant Susceptible S-DD Intermediate Resistant
Amphotericin B C. albicans £1 – >1 NEY NEY NEY NEY
C. glabrata £1 – >1 NEY NEY NEY NEY
C. krusei £1 – >1 NEY NEY NEY NEY
C. parapsilosis £1 – >1 NEY NEY NEY NEY
C. tropicalis £1 – >1 NEY NEY NEY NEY
Itraconazole C. albicans NEY NEY NEY £0.12 0.25–0.50 – ‡1
C. glabrata NEY NEY NEY £0.12 0.25–0.50 – ‡1
C. krusei NEY NEY NEY £0.12 0.25–0.50 – ‡1
C. parapsilosis NEY NEY NEY £0.12 0.25–0.50 – ‡1
C. tropicalis NEY NEY NEY £0.12 0.25–0.50 – ‡1
Fluconazole C. albicans £2 4 >4 £2 4 – ‡8
C. glabrata IE IE IE – £32 – ‡64
C. krusei PT PT PT PT PT PT PT
C. parapsilosis £2 4 >4 £2 4 – ‡8
C. tropicalis £2 4 >4 £2 4 – ‡8
Voriconazole C. albicans £0.125 – >0.125 £0.12 – 0.25–0.50 ‡1
C. glabrata IE IE IE IE IE IE IE
C. krusei IE IE IE £0.50 IE 1 ‡2
C. parapsilosis £0.125 – >0.125 £0.12 – 0.25–0.50 ‡1
C. tropicalis £0.125 – >0.125 £0.12 – 0.25–0.50 ‡1
Posaconazole C. albicans £0.06 – >0.06 NEY NEY NEY NEY
C. glabrata IE IE IE NEY NEY NEY NEY
C. krusei IE IE IE NEY NEY NEY NEY
C. parapsilosis £0.06 – >0.06 NEY NEY NEY NEY
C. tropicalis £0.06 – >0.06 NEY NEY NEY NEY
Caspofungin C. albicans NEY NEY NEY £0.25 – 0.50 ‡1
C. glabrata NEY NEY NEY £0.12 – 0.25 ‡0.50
C. krusei NEY NEY NEY £0.25 – 0.50 ‡1
C. parapsilosis NEY NEY NEY £2 – 4 ‡8
C. tropicalis NEY NEY NEY £0.25 – 0.50 ‡1
Micafungin C. albicans NEY NEY NEY £0.25 – 0.50 ‡1
C. glabrata NEY NEY NEY £0.06 – 0.12 ‡0.25
C. krusei NEY NEY NEY £0.25 – 0.50 ‡1
C. parapsilosis NEY NEY NEY £2 – 4 ‡8
C. tropicalis NEY NEY NEY £0.25 – 0.50 ‡1
Anidulafungin C. albicans £0.03 – >0.03 £0.25 – 0.50 ‡1
C. glabrata £0.06 – >0.06 £0.12 – 0.25 ‡0.50
C. krusei £0.06 – >0.06 £0.25 – 0.50 ‡1
C. parapsilosis PT PT PT £2 – 4 ‡8
C. tropicalis £0.06 – >0.06 £0.25 – 0.50 ‡1
NEY, breakpoints have not been established yet; IE, insufficient evidence to set breakpoints; PT, susceptibility testing not recommended as the species is a poor target for
therapy with the drug; S-DD, susceptible dependant on dose.
Data in mg/L.
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Abstract
This part of the EFISG guidelines focuses on non-neutropenic adult patients. Only a few of the numerous recommendations can be sum-
marized in the abstract. Prophylactic usage of fluconazole is supported in patients with recent abdominal surgery and recurrent gastroin-
testinal perforations or anastomotic leakages. Candida isolation from respiratory secretions alone should never prompt treatment. For
the targeted initial treatment of candidaemia, echinocandins are strongly recommended while liposomal amphotericin B and voriconaz-
ole are supported with moderate, and fluconazole with marginal strength. Treatment duration for candidaemia should be a minimum of
14 days after the end of candidaemia, which can be determined by one blood culture per day until negativity. Switching to oral treat-
ment after 10 days of intravenous therapy has been safe in stable patients with susceptible Candida species. In candidaemia, removal of
indwelling catheters is strongly recommended. If catheters cannot be removed, lipid-based amphotericin B or echinocandins should be
preferred over azoles. Transoesophageal echocardiography and fundoscopy should be performed to detect organ involvement. Native
valve endocarditis requires surgery within a week, while in prosthetic valve endocarditis, earlier surgery may be beneficial. The antifun-
gal regimen of choice is liposomal amphotericin B +/) flucytosine. In ocular candidiasis, liposomal amphotericin B +/) flucytosine is rec-
ommended when the susceptibility of the isolate is unknown, and in susceptible isolates, fluconazole and voriconazole are alternatives.
Amphotericin B deoxycholate is not recommended for any indication due to severe side effects.
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Introduction
Invasive candidiasis remains a challenging complication, which
frequently occurs in patients with one or more underlying
diseases or surgical interventions. In recent point prevalence
studies, a candidaemia incidence of 6.9 per 1000 ICU
patients was reported, and 7.5% of ICU patients received
antifungal therapy [1,2]. Candidaemia increases mortality
rates in the range of 20–49% [3,4], but still there are many
open management questions.
The unmet medical needs surrounding candidaemia and
invasive candidiasis are defined in general from diagnosis to
prophylaxis, empiric and pre-emptive strategies to treatment.
So far, the scientific community has not achieved to accurately
predict invasive candidiasis and thus to define populations that
benefit from prophylaxis or early treatment [5]. Although it is
well known that treatment is being initiated too late in the
majority of patients, identification of the optimal time point to
commence antifungal therapy remains challenging [6,7]. Inter-
twined with this problem is insufficient support of reliable
mycological assays preventing timely and diagnosis-driven early
treatment initiation [173].
With the diversity of various groups of patients with
organ involvement beyond the bloodstream, a body of
diverse evidence on the best treatments and infectious dis-
eases management decisions, for example, treatment dura-
tion is provided.
In the light of the medical need to analyse the scientific
evidence in the field of invasive Candida diseases, the ESC-
MID European Fungal Infection Study Group (EFISG) devel-
oped comprehensive practical guidance for microbiologists
and clinicians to facilitate evidence-based decision making.
This guideline follows the clinical events in a chronological
order. Prophylaxis in patient populations at risk for invasive
Candida disease is followed by fever- and diagnosis-driven
approaches to early therapy and finally targeted therapy.
Important clinical questions on catheter management to
step-down strategies are being addressed. Specific situations
in deep tissue candidiasis are cherished, and for each topic, a
table lists the medical/scientific evidence.
Methods
An expert group (OAC, MB, TC, JG, BJK, OL and WM) was
set up by EFISG and searched the literature. Documents and
views were shared by email, teleconferences, and face-to-face
meetings during 2010–2012. Once a first consensus was
reached, the preliminary recommendations were presented
to the whole group, that is, the other authors, discussed,
developed further, and finalized as a group consensus. The
methods to evaluate the quality of evidence and to reach
group consensus recommendations are described in this issue
of Clinical Microbiology and Infection [172]. Definition of the
strength of recommendation is given in Table 1. The quality
of the published evidence is defined in Table 2. Grouping
quality of evidence into three levels only may lead to diverse
types of published evidence being assigned specifically a level
II. To increase transparency in the evaluation of the evidence,
we added an index (Table 2) to the level II recommendations,
where appropriate. Of note, the strength of recommendation
and the quality of evidence were assigned in two separate
evaluations, thus allowing, for example, a recommendation
strongly supporting a procedure even if there is a lower level
of evidence.
Results
Prophylaxis
Antifungal prophylaxis has been discussed as a promising
approach in ICU patients. At this moment, the optimal target
population for antifungal prophylaxis remains unknown, as
this question has not been sufficiently addressed in clinical
trials. Some special populations though have been enrolled in
randomized clinical trials, and recommendations for these
can be given.
TABLE 1. Definition of the strength of recommendation
Grade ESCMID EFISG
A Strongly supports a recommendation for use
B Moderately supports a recommendation for use
C Marginally supports a recommendation for use
D Supports a recommendation against use
TABLE 2. Definition of the quality of evidence
ESCMID EFISG
Level
I Evidence from at least one properly designed randomized, controlled trial
II Evidence from at least one well-designed clinical trial, without
randomization, from cohort or case-controlled analytical studies
(preferably from >1 centre); from multiple time series or from dramatic
results of uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical
experience, descriptive case studies or reports of expert committees
Index (for quality of evidence II)
r Meta-analysis or systematic review of randomized controlled trials
t Transferred evidence, that is, results from different patients’ cohorts, or
similar
immune-status situation
h Comparator group is a historical control
u Uncontrolled trial
a Published abstract (presented at an international symposium or meeting)
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Evidence. Patients who had undergone abdominal surgery
recently and who had recurrent gastrointestinal perforations
or anastomotic leakages were treated either with fluconaz-
ole 400 mg/day or with placebo in order to prevent intraab-
dominal Candida infection. The rate of intraabdominal
candidiasis was significantly lower in the fluconazole prophy-
laxis group. This clinical trial exhibited high technical quality,
but was performed in a very high baseline incidence popula-
tion and is limited by enrolling 43 evaluable patients only
[8]. In a small non-comparative trial, standard dosed caspo-
fungin was evaluated in the same indication, but no evidence
can be derived [9]. In a large prophylaxis trial, critically ill
surgical patients with an expected ICU stay of ‡3 days were
randomized to receive either fluconazole 400 mg/day or pla-
cebo. The primary endpoint was the time to fungal infection,
which was significantly delayed in the fluconazole prophylaxis
group. The trial was well designed and enrolled 260 patients.
A limitation of the study is the inclusion of presumed inva-
sive fungal infection, defined for example, by repeatedly
positive urine cultures and catheter tips with ‡15 yeast col-
onies, into the primary endpoint [10]. In another study,
patients ventilated for 48 h and expected to remain venti-
lated for another ‡72 h received selective digestive decon-
tamination with polymyxin B, neomycin and vancomycin and
were randomized to receive fluconazole 100 mg/day or pla-
cebo. This trial was well designed, and 204 patients were
randomized. Candidaemia was more successfully prevented
in fluconazole recipients, but the selective digestive decon-
tamination regimen used in this clinical trial is not a standard
in most countries [11–13]. Meta-analyses of the clinical trials
above and some other studies on highly selected populations
found fluconazole 400 mg/day to be superior to placebo in
preventing invasive fungal infection in critically ill surgical
patients [14–18]. A more recent clinical trial compared ca-
spofungin 50 mg/day with placebo for prophylaxis in a highly
selected population of ventilated patients receiving antibiot-
ics, having a central venous catheter and fulfilling at least
one of the following criteria: parenteral nutrition, dialysis,
major surgery, pancreatitis, systemic steroids or other
immunosuppressant medication. The primary endpoint of
this trial was the incidence of proven and probable invasive
candidiasis according to EORTC/MSG definitions [19]. The
investigators found a trend only towards a reduced inci-
dence of invasive candidiasis [5]. Other antifungals have been
evaluated in prophylactic indications [20–22]. For ketoconaz-
ole 200 mg/day, evidence of prophylactic benefit is weak
while adverse events and drug interactions limit its use in
general [22]. The same is true for itraconazole 400 mg/day
[21]. Nystatin 4 Mio IU/day has been evaluated, but concept
and patient setting are basically outdated [20]. Intravenous
amphotericin B and the echinocandins have not been suffi-
ciently evaluated in this indication [23]. Antifungal prophy-
laxis in solid organ transplant recipients is not part of this
guideline.
Of note, none of the trials proved a reduction in overall
or attributable mortality. All trials were lacking power to
address the potential emergence of less azole-susceptible
strains during prophylaxis. Apart from historical control
studies in intensive care and abdominal surgical populations,
this has been shown in prophylactic settings in haematology
during substantially longer azole exposure periods [24–26].
Selection of less-susceptible strains remains a caveat against
broadly using antifungals in populations where substantial
benefit has not been proven.
Recommendations. Fluconazole prophylaxis against invasive
candidiasis is recommended in patients who recently under-
went abdominal surgery and had recurrent gastrointestinal
perforations or anastomotic leakages. For further recom-
mendations, refer to Table 3.
Fever-driven approach (empiric)
We defined empiric therapy as a fever-driven approach in
the clinical situation of a patient at risk for invasive candidia-
sis who is persistently febrile with no microbiological evi-
dence of infection.
Evidence. The value of initiating antifungal therapy in this situa-
tion has been addressed in a number of retrospective studies.
Incubation time [27] and time from first positive blood culture
drawn to initiation of empiric antifungal therapy correlated
with mortality increases [6,28]. Similarly, in a population-
based retrospective study, empiric antifungal treatment was
associated with higher survival rates, if the isolate turned out
to be susceptible to the empiric regimen [29]. Another retro-
spective study in patients with septic shock due to any cause
found empiric antifungal therapy was given infrequently, and
those with invasive fungal infection not receiving empiric anti-
fungals had a statistically significantly higher mortality [7].
Although uncontrolled, all of these studies suggest that ini-
tiating empiric therapy may be beneficial to reduce overall
mortality, but none could identify reliable triggers for
antifungal treatment. They analysed patients with candidaemia
but not the whole population of febrile patients.
One randomized double-blind placebo-controlled clinical
trial evaluated fluconazole 800 mg/day in 270 adult ICU
patients with an APACHE II score >16. Rates of invasive can-
didiasis were not statistically different between the two
groups. The primary endpoint was driven by resolution of
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fever, and empirical fluconazole treatment did not improve
outcome when compared with placebo [30].
Recommendations. Early treatment of presumed fungaemia is
presumably associated with higher survival rates, but the
optimal time point for initiating empiric antifungal treatment
remains undetermined. Due to lack of data, no recommenda-
tion can be given for choosing a specific drug for fever-dri-
ven therapy. In general, such choice should be based on local
epidemiology and drug–drug interactions in the individual
patient and should be made among the same drugs as rec-
ommended for candidaemia. Further recommendations are
given in Table 4.
Diagnosis-driven approach (pre-emptive)
We defined pre-emptive therapy as therapy triggered by
microbiological evidence of candidiasis without proof of inva-
sive fungal infection.
Evidence. Several studies have addressed diagnosis-driven ther-
apy on grounds of detecting (1,3)-b-D-glucan in serum or
plasma. In a study on 46 ICU patients without infection or with
confirmed bacterial or fungal infection, glucan test results (G-
test; Associates of Cape Cod, East Falmouth, MA, USA) corre-
lated with infection, but not with fungal infection. The authors
suggested using the test to rule out invasive fungal infection
[31]. This was the key finding in a study using the FungitellTM
TABLE 3. Recommendations on antifungal prophylaxis in ICU patients
Population Intention Intervention SoR QoE References Comment
Recent abdominal surgery AND recurrent
gastrointestinal perforations or
anastomotic leakages
To prevent intraabdominal Candida infection Fluconazole 400 mg/day B I [8] Placebo
N = 43
Caspofungin 70/50 mg/day C IIu [9] Single arm
N = 19
Critically ill surgical patients with an
expected length of ICU stay ‡3 day
To delay the time to fungal infection Fluconazole 400 mg/day C I [10] Placebo
N = 260
Ventilated for 48 h and expected to be
ventilated for another ‡72 h
To prevent invasive candidiasis/candidaemia Fluconazole 100 mg/day C I [162] Placebo
N = 204
SDD used
Ventilated, hospitalized for ‡3 day, received
antibiotics, CVC, and ‡1 of: parenteral
nutrition, dialysis, major surgery,
pancreatitis, systemic steroids,
immunosuppression
To prevent invasive candidiasis/candidaemia Caspofungin 50 mg/day C IIa [5] Placebo
N = 186
EORTC/MSG
criteria used
Surgical ICU patients To prevent invasive candidiasis/candidaemia Ketoconazole 200 mg/day D I [22] Placebo
N = 57
Critically ill patients with risk factors for
invasive candidiasis/candidaemia
To prevent invasive candidiasis/candidaemia Itraconazole 400 mg/day D I [21] Open
N = 147
Surgical ICU with catabolism To prevent invasive candidiasis/candidaemia Nystatin
4 Mio IU/day
D I [20] Placebo
N = 46
SoR, Strength of recommendation; QoE, Quality of evidence; ICU, intensive care unit; CVC, central venous catheter; IU, international units.
The table displays the published evidence; therefore, other available antifungal agents are not mentioned here.
TABLE 4. Recommendations on fever-driven and diagnosis-driven therapy of candidaemia and invasive candidiasis
Population Intention Intervention SoR QoE References
Adult ICU patients with fever despite
broad-spectrum antibiotics and APACHE
II >16
To resolve fever Fluconazole 800 mg/day D I [30]
ICU patients persistently febrile, but without
microbiological evidence
To reduce overall mortality Fluconazole or echinocandin C IIu [28]
[163]
[164]
[7]
[27]
ICU patients with candida isolated from
respiratory secretions
To cure invasive candidiasis or candidaemia early Any antifungal D IIu [42]
ICU patients with positive (1,3)-b-D-glucan
testa
To cure invasive candidiasis or candidaemia early Any antifungal C IIu [39]
[31]
[37]
[35]
[32]
[36]
[34]
[33]
Any patient with Candida isolated from
a blood culture
To cure invasive candidiasis Antifungal treatment A II [46]
[47]
[48]
[49]
APACHE, acute physiology and chronic health evaluation.
aThe (1,3)-b-D-glucan tests have low specificity and sensitivity with false-positive results in the presence of haemodialysis, other fungal or bacterial infection, wound gauze,
albumin or immunoglobulin infusion.
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(Assoc. of Cape Cod) test, too [32]. Another group of investi-
gators found glucan (FungitecTM; Seigakaku Kogyo, Tokyo,
Japan) testing useful in predicting invasive fungal infection, but in
a very small population of 32 patients only [33]. During twice
weekly monitoring in long-term ICU patients, glucan concen-
trations (GlucatellTM; Cape Cod) were higher in individuals
with proven fungal infection than in those without. As patients
with invasive fungal infection had more bacterial infections and
other intercurrent complications, the test result could still not
clearly distinguish between both groups [34]. Similar results
were found in a surgical ICU patient group (N = 57) and in a
mixed ICU population (N = 95) where higher glucan concen-
trations (Fungitell) were found in those with invasive candidi-
asis, but still the positive predictive value was limited [35,36].
Findings from a retrospective study on a larger number of
patients (N = 871) were in favour of the test (Fungitell), but
documented generally higher glucan concentrations in patients
on haemodialysis and in those receiving albumin or intravenous
immunoglobulin infusions [37]. Other reasons for positive test
results in the absence of invasive candidiasis have been
described due to (1,3)-b-D-glucan-containing cell walls of a vari-
ety of fungi, for example, Aspergillus or Histoplasma [32,38].
Indeed, the Fungitell assay has been suggested useful in the
diagnosis of pneumocystis pneumonia as well [39]. A discussion
of glucan tests and their cut-offs to positivity can be found in
the ESCMID Candida Guidelines on Diagnostic Procedures in
this issue [173]. In some of the studies above, it has been stated
that a negative glucan test practically rules out invasive candidi-
asis. Currently, the glucan tests cannot reliably confirm invasive
candidiasis, although there may be a role as part of a set of
diagnostic tools and patient characteristics.
Recommendations on mannan and anti-mannan antibody
detection is part of the EFISG guideline on diagnosis of inva-
sive candidiasis [173].
A controversial issue is the initiation of antifungal therapy
upon Candida isolation from respiratory secretions. Two forms
of pulmonary candidiasis have been distinguished, that is, pul-
monary abscesses resulting from haematogenous spread during
candidaemia, especially in febrile neutropenic patients, and
direct invasion of bronchial and lung tissues. Most articles on
the topic of pulmonary candidiasis were published in the 1970s
and 1990s. There are hardly any data on ICU populations, but
case series of patients with haematological malignancy and stem
cell recipients [40,41]. While Candida can frequently be isolated
from respiratory secretions, it appears that Candida invading
the lung tissue is a very rare event. In a recent prospective
autopsy study (N = 232) on ICU patients, a total of 58% had
proven pneumonia. Regardless of whether Candida had been
isolated pre-mortem or not, in neither case histopathological
proof of Candida tissue invasion was found [42].
Recommendations. Candida isolation from respiratory
secretions should never trigger treatment, but rather be
interpreted as one site of colonization among others. (1,3)-
b-D-glucan detection in serum or plasma prompting antifungal
treatment is marginally supported. Detailed recommenda-
tions are given in Table 4.
Targeted treatment
Candida isolated from a single peripheral blood culture or a
single central-line blood culture defines candidaemia
[19,43,44]. Previous definitions may have described asymp-
tomatic patients with a blood culture positive for Candida,
and it has been debated whether there are patients who do
not need antifungal treatment despite a positive blood cul-
ture [45]. This appears to be a very rare clinical situation, as
usually blood cultures are triggered by a clinical sign, for
example, fever. Each case of candidaemia, even from surveil-
lance blood cultures in asymptomatic patients requires tar-
geted treatment [46–49].
Evidence. A plenitude of well-designed clinical trials evaluated
antifungals for the initial treatment of candidaemia and inva-
sive candidiasis. Amphotericin B deoxycholate clearly is a
very potent drug against Candida, but the well-documented
significant toxicity justifies a recommendation against using
this compound [50–55]. In the past, several approaches
aimed at reducing toxicity, for example, continuous intrave-
nous administration, but efficacy of this strategy in candidiasis
remains unclear [56]. Amphotericin B lipid complex has been
evaluated in candidaemia, but the single randomized trial to
date has been published as abstract only. Amphotericin B
lipid complex appeared to be less nephrotoxic than the de-
oxycholate formulation although not more effective [57],
findings which were supported by a phase IV study [58]. As
opposed to laboratory-confirmed adverse events, clinically
defined side effects, such as infusion-related fever and chills,
tend to be underestimated in uncontrolled post-marketing
studies. When ABLC was compared to liposomal amphoteri-
cin B in persistently febrile neutropenic patients, infusion-
related adverse events occurred very frequently [59]. Data
on amphotericin B colloidal dispersion stem from a non-ran-
domized, non-comparative study describing nephrotoxicity in
the same range as found with amphotericin B lipid complex
[60]. Liposomal amphotericin B and amphotericin B deoxych-
olate have not been compared directly in patients with candi-
daemia. But, liposomal amphotericin B appears at least as
effective, but less toxic than the deoxycholate formulation
when considering results from a large clinical trial on candi-
daemia and invasive candidiasis evaluating liposomal ampho-
tericin B and micafungin [61]. Compared to micafungin,
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efficacy was similar, but renal toxicity was higher with liposo-
mal amphotericin B [61,62]. Caspofungin when compared to
amphotericin B deoxycholate was as effective, but signifi-
cantly less toxic [55]. A clinical strategy became feasible,
which avoided amphotericin B toxicity without losing effi-
cacy. Two doses of micafungin (100, 150 mg/day) were com-
pared with caspofungin in a phase III trial. All three regimens
were similarly effective and safe [63]. While all echinocandin
trials above proved statistical non-inferiority of the experi-
mental study drug as compared to standard regimens, anidu-
lafungin was found to be superior over fluconazole [64]. In
particular, the outcomes for patients with Candida albicans
were significantly better with anidulafungin (81%) than with
fluconazole (62%). The latter result remained valid in a sub-
sequent subgroup analysis of ICU patients: global response
for anidulafungin 67% vs. fluconazole 47% [65].
With regard to Candida, all three echinocandins exhibit a
broad spectrum activity; acquired resistance is rare, although
there has been a first large epidemiological evaluation
describing acquisition of resistance genes in Candida glabrata
[66]. There is an ongoing debate on whether echinocandins
are appropriate for treating Candida parapsilosis, because min-
imal inhibitory concentrations are found to be higher than
those of other Candida species. Overall, that is, clinical and
microbiological, response rates in C. parapsilosis infection
were not statistically significantly different throughout the
echinocandin trials: for caspofungin/amphotericin B, the suc-
cess rates were 70% and 65%, for micafungin/liposomal
amphotericin B 89.2% and 86.7%, for caspofungin/micafungin
100/150 rates were 64.3%, 75.9% and 71.4%, and for anidula-
fungin/fluconazole, they were 64% and 83% [55,61,63]. How-
ever, there were numerically higher numbers of persistent
fungaemia due to C. parapsilosis during caspofungin as com-
pared to amphotericin B deoxycholate treatment [55], and
during standard dose caspofungin as compared to high dose,
that is, 150 mg/day, caspofungin [67], and the eradication
rate in C. parapsilosis fungaemia was lower with anidulafungin
than with fluconazole [64]. It is important to note that none
of these trials were powered to detect such differences.
Two further aspects we considered important when
interpreting the latter trial are (i) the microbiological eradi-
cation rate as well as the overall success rate in C. albicans
infection was higher with anidulafungin than with fluconaz-
ole and (ii) Candida krusei infection was excluded from the
anidulafungin trial, because of fluconazole being the compar-
ator drug [64].
In the clinical trials, all three echinocandins were well tol-
erated and appeared very safe. Micafungin though carries a
warning label against use unless other antifungals are not
appropriate by the European Medicines Agency, which
reflects results of rats developing liver tumours after very
long and high-dosed exposure [68]. This statement has elic-
ited some debate in terms of its relevance to humans, but
has not been withdrawn or disproved so far.
An advantage of the echinocandin class is the low poten-
tial for drug–drug interactions. For anidulafungin, no interac-
tions have been described, and for micafungin, very few
relevant interactions need to be considered [68,69]. Co-
administering caspofungin with rifampin lowers caspofungin
exposure, and it has been recommended to increase the
dose of caspofungin in the rare cases, where both drugs
need to be administered concomitantly. In addition, caspo-
fungin dose has to be increased in patients with a high body
weight [70].
For many years, fluconazole was considered the drug of
choice for candidaemia [71–73]. This was based on a great
number of clinical trials evaluating fluconazole in this indication
[52–54,64,74–76]. As anidulafungin was superior over fluco-
nazole in patients with candidaemia, especially those infected
with C. albicans, we do no longer consider fluconazole as the
drug of choice [64]. Fluconazole was inferior in the subgroup
of patients with high APACHE scores and is known to have a
limited spectrum of activity, being inactive against C. krusei and
being considered hardly active in C. glabrata infection. Microbi-
ologically, it might though be the better drug against C. par-
apsilosis, which is supported by a trend towards better
outcomes in the comparative trial [64], but clinical proof is
not in support of this. There have been no trials with suffi-
cient power to assess non-inferiority of echinocandins for
C. parapsilosis. In a large clinical trial, voriconazole was non-
inferior to amphotericin B deoxycholate followed by fluconaz-
ole [43], and voriconazole offers an important additional treat-
ment option for first-line and salvage situations [77,78]. Still
there are certain limitations, that is, the multiple drug–drug
interactions [79], the limit of the intravenous use to 14 days
duration [79] and the variable pharmacokinetics of the drug
[80]. Itraconazole yielded negative results when compared to
fluconazole [76]. There are no published data on posaconaz-
ole treatment of candidaemia.
Very few clinical trials used combination treatment. Lipid-
based amphotericin B was supplemented with placebo or
efungumab, a monoclonal antibody targeting heat shock pro-
tein 90 (HSP-90), in 139 patients. The study design and anal-
ysis drew substantial criticism for (i) enrolling an ill-defined
patient population, for example, symptomatic candiduria, (ii)
enrolling patients with negative fungal cultures and (iii)
excluding patients from the efficacy population who died
while on treatment [81]. Furthermore, the trial allowed
extensive prior antifungal treatment, used a short, 10-day,
treatment time until response evaluation and did not specify
24 Clinical Microbiology and Infection, Volume 18 Supplement 7, December 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 7), 19–37
the proportion of patients receiving which type of lipid-based
amphotericin B formulation.
The combination of amphotericin B deoxycholate and
fluconazole has been as effective as fluconazole monotherapy
in a randomized trial, but patients had an increased risk of
toxicity and no survival benefit [74]. A small study (N = 72)
comparing fluconazole with amphotericin B deoxycholate
and 5-flucytosine showed no difference in overall response
to treatment [75].
Recommendations. Targeted treatment of candidaemia with
echinocandins is strongly recommended. The recommenda-
tion for liposomal amphotericin B or voriconazole is less
stringent, and fluconazole is recommended with marginal
strength only, except for C. parapsilosis. For detailed recom-
mendations, refer to Table 5.
Duration of targeted treatment, step-down to oral treat-
ment and diagnostics in candidaemia
Evidence. The duration of treatment depends on the extent
of organ involvement. In a population without documented
organ involvement, treatment aims to clear the infection
and at the same time to avoid deep-organ involvement. This
can be achieved by treating for 14 days after the end of
candidaemia [82]. To determine the end of candidaemia, at
least one blood culture per day should be taken until cul-
ture results come back negative. Treatment can probably
be simplified by stepping down to oral fluconazole after
10 days of intravenous treatment, if the patient is stable,
tolerates the oral route and if the species is susceptible
[55,63,64].
The diagnostic procedures to detect organ involvement
comprise transoesophageal echocardiography, fundoscopy
and search for a thrombus. A recent observational study
found infectious endocarditis in 8.3% of patients with candi-
daemia; the majority of these patients had no well-estab-
lished risk factors, that is, vascular prosthesis or persistent
candidaemia [83].
Some prospective studies addressed ocular candidiasis as
complication of candidaemia. The diagnostic approach was
usually based on weekly eye examinations. Immunosuppres-
sion and repeatedly positive blood cultures are risk factors
TABLE 5. Recommendations on initial targeted treatment of candidaemia and invasive candidiasis in adult patients
Intervention SoR QoE References Comment
Anidulafungin 200/100 mg A I [64] Consider local epidemiology (Candida parapsilosis, Candida krusei), less
drug–drug interactions than caspofungin
Caspofungin 70/50 mg A I [67]
[55]
[63]
Consider local epidemiology (C. parapsilosis)
Micafungin 100 mg A I [61]
[63]
Consider local epidemiology (C. parapsilosis), less drug–drug interactions
than caspofungin, consider EMA warning label
Amphotericin B liposomal 3 mg/kg B I [61]
[62]
Similar efficacy as micafungin, higher renal toxicity than micafungin
Voriconazole 6/3 mg/kg/daya,b B I [43]
[78]
[77]
Limited spectrum compared to echinocandins, drug–drug interactions,
limitation of IV formulation in renal impairment, consider therapeutic drug
monitoring
Fluconazole 400–800 mga C I [165]
[53]
[74]
[54]
[64]
[76]
[75]
[73]
[72]
Limited spectrum, inferiority to anidulafungin (especially in the subgroup
with high APACHE scores), may be better than echinocandins against
C. parapsilosis
Amphotericin B lipid complex 5 mg/kg C IIa [57]
[58]
Amphotericin B deoxycholate 0.7–1.0 mg/kg D I [50]
[51]
[165]
[53]
[54]
[55]
Substantial renal and infusion-related toxicity
Amphotericin B deoxycholate plus fluconazole D I [74] Efficacious, but increased risk of toxicity in ICU patients
No survival benefit
Amphotericin B deoxycholate plus 5-fluorocytosine D II [75]
Efungumab plus lipid-associated amphotericin B D II [166]
Amphotericin B colloidal dispersion D IIa [60]
Itraconazole D IIa [76]
Posaconazole D III No reference found
EMA, European Medicines Agency.
Comparative clinical trials did not prove a survival benefit of one treatment over another. Primary intention of treating candidaemia is clearing the blood stream.
aNot all experts agreed, SoR results from a majority vote.
bThe licensed maintenance dosing is 4 mg/kg/day.
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for eye involvement and should prompt fundoscopic evalua-
tion [84,85]. Other risk factors coincided with those for can-
didaemia [86]. In a large clinical trial, fundoscopy revealed
ocular candidiasis in 16% of patients with candidaemia, the
majority had eye involvement upon diagnosis of candidaemia
and additional cases were detected during treatment. Most
of the patients had chorioretinitis while endophthalmitis was
uncommon (1.6%) [43,87].
In patients with a central venous catheter or a peripherally
inserted central catheter, the possibility of a thrombus
should be taken into account.
Recommendations. For uncomplicated candidaemia, treat-
ment duration of 14 days after the end of candidaemia is
recommended. The end of candidaemia should be deter-
mined by at least one blood culture per day until nega-
tivity. Transoesophageal echocardiography and fundoscopy
should be performed to detect organ involvement.
Switching to oral treatment can be considered after
10 days of intravenous therapy. For detailed recommenda-
tions, refer to Table 6.
Catheter-related blood stream infection
In general, indwelling lines need to be removed early after
diagnosing catheter-related candidaemia; however, removal
or exchange is not always possible. As the predominant
mode of device-related infections is likely biofilm formation
[88], certain differences in antifungal activity on Candida
grown in biofilms vs. planktonic cells may help decision mak-
ing. Liposomal amphotericin B, amphotericin B lipid complex,
caspofungin and micafungin were active against Candida cells
in biofilms, while cells were resistant towards amphotericin
B deoxycholate, fluconazole, ravuconazole and voriconazole
[89]. In animal models, amphotericin B lipid complex and ani-
dulafungin reduced candida cell numbers in biofilms, while
fluconazole did not [90,91].
Evidence. Duration of candidaemia: In a prospective random-
ized clinical trial comparing fluconazole with amphotericin B
deoxycholate for candidaemia in non-neutropenic patients
[53], the exchange of catheters – not over a guidewire –
within the first 24 h was associated with a shorter duration
of candidaemia [92]. A post hoc analysis of two pooled phase
III trials comparing micafungin to caspofungin or liposomal
amphotericin B (N = 842) did not find an improved time to
mycological eradication, if central venous catheters were
removed within 24 or 48 h [61,63,93].
Impact of catheter removal on mortality: Catheter removal
was identified as a protective factor in a prospective study
on 272 episodes of candidaemia [94]. A population-based
study analysing 345 cases of candidaemia concluded that
catheter removal was associated with an improved probabil-
ity of survival [95,96]. In a retrospective analysis on 92
patients with cancer, removal of non-tunnelled central
venous catheters ‡72 h after diagnosis of candidaemia was
associated with a significantly decreased survival rate, [97]
and in a univariate analysis on 244 ICU patients with candida-
emia, catheter removal within 24 h was associated with bet-
ter survival [73]. Early removal of central venous catheters,
that is, within 24 or 48 h, had no impact on survival at 28 or
42 days in the post hoc analysis of the two pooled micafungin
phase III trials [93]. However, in a recent individual patient
level (n = 1915) pooled analysis of seven prospective ran-
domized controlled trials for treatment of invasive candidiasis
and candidaemia, the removal of a central venous catheter
was associated with decreased mortality (OR, 0.50; 95% CI,
0.35–0.72, p = 0.0001) [98].
Recommendations. In candidaemia, removal of indwelling intra-
vascular catheters is strongly recommended. When catheter
removal is not possible, lipid-based amphotericin B formula-
tion or an echinocandin is preferable. For detailed recom-
mendations, refer to Table 7.
TABLE 6. Recommendations on the duration of targeted treatment, step-down to oral treatment and diagnostics in
candidaemia
Population Intention Intervention SoR QoE References
Candidaemia with no
organ involvement
detected
To avoid organ
involvement
Treat for 14 days after the end of candidaemia B II [82]
Take at least one blood culture per day until negative B III No reference found
To detect organ
involvement
Transoesophageal echocardiography B IIa [83]
Fundoscopy B II [87]
[84]
[85]
[86]
If CVC, PICC or intravascular devices, search for
thrombus
B III No reference found
Any To simplify treatment *Step-down to fluconazole after 10 days of IV, if species
is susceptible, patient tolerates PO, and patient is stable
B II [64]
[55]
[63]
CVC, central venous catheter; PICC, peripherally inserted central catheter.
*If C. parapsilosis is identified, step-down to fluconazole may occur earlier.
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Urinary tract infection
Candiduria is commonly encountered in hospitalized patients,
particularly those with a urinary catheter. Candiduria is indic-
ative for a wide spectrum of conditions which may or may
not require treatment.
Evidence. Asymptomatic candiduria has been followed long
term, but no adverse consequences have been described [99].
Funguria resolved without specific treatment in 76% of a large
(N = 861) clinical cohort [100]. In a well-designed trial, fluco-
nazole was superior over placebo in clearing candiduria, but at
2-week follow-up candiduria rates were similar between both
groups. Removal of the urinary catheter was the most promis-
ing intervention [101]. Bladder irrigation appeared as a rarely
used alternative, if treatment is judged necessary [100,102]. In
symptomatic candida cystitis, fluconazole has been advocated
as well as amphotericin B deoxycholate with or without 5-flu-
cytosine, but clinical data are sparse for all these approaches
[100,103]. In the rare cases of fungus balls, surgical interven-
tion is the only promising treatment option [104,105]. Echino-
candins do not achieve high urine concentrations and are thus
rarely considered in urinary tract infection. Some cases though
have successfully been treated with caspofungin. These were
partly candidaemias with concomitant candiduria and partly
infections limited to the urinary tract [106]. For candida
pyelonephritis, fluconazole and amphotericin B deoxycholate
each with or without flucytosine may be used, but clinical tri-
als have not been performed.
Recommendations. Asymptomatic candiduria should not be
treated, while symptomatic cystitis should be treated with
fluconazole, if the isolate is susceptible. Fungus balls or casts
in the pyelum or urinary bladder need surgical intervention.
To cure pyelonephritis fluconazole as well as lipid-based
amphotericin B are recommended either alone or in combi-
nation with flucytosine. For detailed recommendations, refer
to Table 8.
Ocular candidiasis
Ocular candidiasis may cause pain or disturbed vision, but
should rather be diagnosed prior to becoming clinically
symptomatic [86,107]. There are two forms of ocular candi-
diasis. Chorioretinitis is the inflammation of the choroid and
the retina, while endophthalmitis is the inflammation of the
vitreous body. Fungal endophthalmitis may develop from
chorioretinitis as advanced disease and is associated with
poor visual outcomes [108]. Most publications in this field
report on individual cases or small series, and not all clearly
differentiate between the two forms of ocular involvement.
Evidence. Amphotericin B deoxycholate has been advocated
for ocular candidiasis, but dosing information was not always
disclosed in the early reports [107,109,110]. Amphotericin B
deoxycholate followed by fluconazole has been used success-
fully to treat ocular involvement in the voriconazole phase III
trial [43,87]. Information on amphotericin B lipid complex
use in ocular candidiasis is sparse. One case of breakthrough
ocular candidiasis during amphotericin B lipid complex treat-
ment has been described [111], and another case in which
amphotericin B lipid complex was successfully used with con-
comitant flucytosine [112]. In a rabbit model evaluating the
penetration of amphotericin B deoxycholate, liposomal
amphotericin B and amphotericin B lipid complex, the high-
est penetration into the eye was achieved with the liposomal
formulation [113,114]. Intravitreal injection of amphotericin
B deoxycholate 5–10 lg dissolved in 0.1 mL sterile water is
part of standard approaches and frequently combined with
systemic antifungals and surgery [110,115].
All three echinocandins appear to have limited penetration
into the eye [116–118]. With caspofungin treatment, varying
outcomes have been reported, some patients failed treat-
ment [116,119], while only two patients have been described
who responded successfully [120,121].
Successful use of fluconazole has been reported in case ser-
ies, where it was used at doses varying from 100 to 400 mg
TABLE 7. Recommendations on catheter management in candidaemia
Population Intervention SoR QoE References
Central venous catheter can be removed Remove indwelling lines (not over a guidewire) A IIr [98]
Central venous catheter cannot be removed Echinocandin, liposomal amphotericin B or amphotericin
B lipid complex
B IIr [98]
[90]
[89]
[91]
[93]
[92]
Azole or amphotericin B deoxycholate D IIr [95]
[98]
[73]
[97]
[96]
[94]
Interventions are intended to clear candidaemia and to improve survival.
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for at least two and up to 8 weeks. A number of these patients
were treated with concomitant systemic amphotericin B de-
oxycholate [122–125]. Overall fluconazole 400 mg alone
appeared to be effective in less-advanced disease [126].
In advanced disease, a combined strategy of surgical inter-
vention with intraocular amphotericin B deoxycholate, and
systemic fluconazole has successfully been applied [110]. Sys-
temic antifungal treatment duration varied between 2 and
12 weeks [110,127]; an individual decision will usually take
reduction of immunosuppression and the extent of ocular
candidiasis into consideration.
More recently, intravitreal voriconazole has been evalu-
ated, and in animal models, doses of 25 mg/L vitreous, that
is, 100 lg absolute in an adult human eye, were found to be
safe [126,128]. Published cases were frequently treated with
combined approaches, so that the efficacy of voriconazole
monotherapy has not yet been defined [126,129,130]. In the
post hoc analysis of eye involvement in the voriconazole
phase III trial on candidaemia, treatment was successful in
most cases, but endophthalmitis was rare [87].
Recommendations. In ocular candidiasis, liposomal amphoteri-
cin B either alone or combined with flucytosine is recom-
mended when the susceptibility of the isolate is unknown.
In susceptible isolates fluconazole or voriconazole are the
drugs of choice. In the case of vitreal involvement, vitrec-
tomy and intravitreal injection of amphotericin B are rec-
ommended in addition to systemic therapy. For details,
refer to Table 9.
Candida meningitis
Candida meningitis is a rare disease, and only very few
reports have been published. Prognosis is generally poor
[131].
Evidence. Liposomal amphotericin B has been combined with
flucytosine for 10 weeks, followed by fluconazole for
5 weeks in a neonate [132]. In another neonate, a Candida
isolate was resistant to flucytosine, and liposomal amphoteri-
cin B was combined with fluconazole for a total of 4 weeks
[133]. Amphotericin B deoxycholate/flucytosine treatment
had failed in the latter patient [133]. However, it is unclear
to what extent these experiences can be extrapolated
applied to adults. In a series of HIV-infected patients with
candida meningitis, amphotericin B deoxycholate was fre-
quently combined with flucytosine, and four of five patients
were treated successfully [131]. In two other series, 27 of
34 patients survived after similar treatments [134,135]. In
some cases, individualized maintenance regimens were given
[131,134]. In the more recent case reports, amphotericin B
deoxycholate toxicity frequently forced to replace it with
the liposomal amphotericin B.
Fluconazole has been used in higher doses to treat Can-
dida meningitis, when lower doses proved insufficient [136].
Published data on voriconazole use in Candida meningitis are
sparse. In central nervous system, aspergillosis voriconazole
is the drug of choice [137]. Brain tissue levels of voriconaz-
ole are satisfactory, but concentrations in cerebrospinal fluid
are variable [138].
With caspofungin, a patient was cured from Candida men-
ingitis refractory to amphotericin B deoxycholate and fluco-
nazole [139], but poor penetration of echinocandins limit
their use in central nervous system infection.
Recommendations. Due to lack of data, no strong recommen-
dation can be given. Treatment should build on liposomal
amphotericin B combined with flucytosine or with fluconaz-
ole if isolate is susceptible. For detailed recommendations,
refer to Table 10.
TABLE 8. Recommendations on Candida urinary tract infections
Population Intention Intervention SoR QoE References
Asymptomatic To clear candiduria Nonea A IIu [100]
[99]
Fluconazole 200 mg for 14 daysb C I [100]
[101]
Removal of urinary catheter B I [101]
Amphotericin B deoxycholate bladder irrigation C IIr,u [100]
[102]
Cystitis To cure Fluconazoleb A III [100]
Amphotericin B deoxycholate +/) flucytosine B III
Fungus balls To cure Surgical intervention A III [104]
[105]
Pyelonephritis To cure Caspofungin 70/50 mg for 9–28 days C III [106]
Fluconazole +/) flucytosineb A III No reference found
Lipid-based amphotericin B +/) flucytosine A III No reference found
aIn pre-operative patients, treatment is indicated to suppress candiduria.
bIf species is susceptible.
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Candida endocarditis
Candida endocarditis may manifest as native valve endocardi-
tis, prosthetic valve endocarditis or infection in the presence
of pacemaker or other implanted material prone to biofilm
formation. In general, prognosis is poor with 1-year mortality
>50% and substantial relapse rates [140–142].
Evidence. In native valve Candida endocarditis, primary inten-
tion is to decrease mortality [140]. Retrospective data sug-
gest that patients should undergo surgery within the first
week [140,141,143]. Treatment regimens published are lipo-
somal amphotericin B or caspofungin, either one has been
combined with flucytosine [140,141]. In prosthetic valve Can-
dida endocarditis, valve replacement surgery needs be per-
formed as soon as possible [142,143]. In single cases where
comorbidities prevented surgery, caspofungin and liposomal
amphotericin B were used successfully with or without sub-
sequent life-long suppressive therapy with fluconazole
[142,144,145]. In patients with pacemakers, implantable defi-
brillators or assist devices, removal of the device appears
mandatory [146].
Recommendations. In native valve Candida endocarditis, sur-
gery within a week is recommended, and in prosthetic valve
Candida endocarditis, even earlier surgery may be beneficial.
The antifungal regimen of choice is liposomal amphotericin
B, which can be combined with flucytosine. For detailed rec-
ommendations, refer to Table 11.
TABLE 9. Recommendations on Candida chorioretinitis and endophthalmitis
Population Intervention SoR QoE References
Susceptibility of isolate unknown Liposomal amphotericin B 5 mg/kg B III [113]
[114]
[119]
Liposomal amphotericin B plus flucytosine B III No reference found
Amphotericin B lipid complex plus flucytosine B III [112]
Amphotericin B deoxycholate 0.7–1.0 mg/kg (for 3–7 days), followed by
fluconazole 400 mg
C II [87]
Amphotericin B deoxycholate 0.6–1.0 mg/kg C IIr [107]
[109]
[110]
Amphotericin B lipid complex 5 mg/kg C III [111]
Amphotericin B deoxycholate plus flucytosine C III No reference found
Caspofungin 50–100 mg D IIu [116]
[120]
[121]
[119]
[130]
Susceptible isolate Fluconazole 400–800 mg A IIu [122]
[123]
[124]
[126]
[125]
Voriconazole 12/6 mg/kg IV, followed by 400 mg PO A IIu [129]
[87]
[130]
[119]
[126]
[128]
Vitreal involvementa Amphotericin B deoxycholate 5–10 lg intravitreal injection B IIu [110]
[167]
[115]
[168]
Vitrectomy plus intravitreal amphotericin B 5–10 lg, fluconazole
400 mg for ‡2 weeks
B IIu [110]
[127]
[125]
Voriconazole 100 lg intravitreal injection B III [128]
[126]
Frequent eye examinations are needed to detect disease progression.
aEndophthalmitis requires local and systemic treatment plus surgery.
TABLE 10. Recommendations on Candida meningitis
Intervention SoR QoE References
Liposomal amphotericin B 3 mg/kg for
10 weeks + flucytosine 150 mg/kg for
10 weeks, followed by fluconazole 3 mg/kg
for 5 weeks
B III [132]
Liposomal amphotericin B 3 mg/kg for
4 weeks + fluconazole 6 mg/kg for 4 weeks
B III [133]
Voriconazole 12/6 mg/kga C III [137]
[138]
[43]
Fluconazole 800 mg C III [136]
[169]
Amphotericin B deoxycholate 0.5–1.0 mg/kg
for >2 weeks +/) flucytosine 30–120
mg/kg for >2 weeks
D IIu [131]
[134]
[133]
[135]
Caspofungin 70/50 mg for 4 weeks, followed
by fluconazole 400 mg for 2 weeks
D III [139]
[170]
Interventions are intended to cure Candida meningitis.
aTherapeutic drug monitoring recommended.
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Bone and joint candidiasis
Candida infections of bones and joints are grouped into osteo-
myelitis/spondylodiscitis, arthritis and prosthetic joint infection.
No randomized clinical trials have been conducted, so that evi-
dence for the best therapeutic approach is somewhat limited.
Evidence. Typical indications for surgical debridement in oste-
omyelitis or spondylodiscitis are instability or large abscesses.
Usually, cases of Candida osteomyelitis are diagnosed by
biopsy. Over the years, most experience has been gathered
with amphotericin B formulations, sometimes combined with
flucytosine, sometimes followed by fluconazole [147]. Today,
in patients with osteomyelitis as well as spondylodiscitis due
to a susceptible isolate, treatment can commence with lipo-
somal or lipid complex amphotericin B to be followed by
fluconazole [147], or – if isolate is susceptible – fluconazole
monotherapy may be used from the beginning [147–149].
Posaconazole has been successfully used in a single case as
add-on during unsuccessful caspofungin treatment [150].
Voriconazole treatment has been reported in three patients
with Candida osteomyelitis [78]. In addition, in Aspergillus
osteomyelitis, voriconazole was used either as the only
antifungal or as maintenance following liposomal amphoteri-
cin B [151]. Use of echinocandins has not been reported,
with the exception of four patients with osteomyelitis and/or
septic arthritis successfully treated with caspofungin [120].
A case of Candida shoulder arthritis was cured with a 3-
week course of caspofungin [152], and a knee arthritis was
treated with 7 weeks of caspofungin added on to a failing
fluconazole therapy [153]. The most prevalent joint prone to
Candida infection is the knee. Standard treatment of knee
arthritis due to Candida was an amphotericin B–based
approach, which may have been supplemented with flucyto-
sine [154]. More recently, fluconazole and voriconazole were
used with success [78,155,156].
Joint prosthesis is an important risk factor for Candida
arthritis, and prosthesis is mandatory [154,157,158]. If the
prosthesis must be retained, life-long suppressive treat-
ment should be tried. In some patients, surgery was con-
sidered not possible, and knee or hip prosthetic joint
arthritis was cured with use of fluconazole alone
[157,159–161]. Bias towards publishing the unusual and
successful cases can be assumed, so that the standard
approach remains prosthesis removal and an intensive
course of systemic antifungals.
Recommendations. Treating osteomyelitis, spondylodiscitis or
arthritis with fluconazole is strongly recommended if species
is susceptible. Fluconazole may be preceded by an induction
phase with lipid-based amphotericin B. If joint prosthesis can-
not be removed, lifelong fluconazole suppressive therapy is
indicated. For details, refer to Table 12.
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TABLE 11. Recommendations on Candida endocarditis
Population Intention Intervention SoR QoE References
Native valve To cure Surgery within 1 week A II [140]
[143]
[171]
Liposomal ampho B +/) flucytosine for 6–8 weeks, followed by fluconazole B II [171]
Caspofungin +/) flucytosine C II [171]
Prosthetic valve To cure Surgery within days A III [142]
[143]
Prosthetic valve, if surgery not possible To cure Liposomal amphotericin B 5 mg/kg B III [142]
Caspofungin 70/50 mg B III [142]
To suppress infection Fluconazole 400–800 mg, life long C III [142]
[145]
Pacemaker, ICD, VAD To cure Removal A II [146]
[144]
ICD, implantable cardioverter defibrillator; VAD, ventricular assist device.
Surgery – even if restricted to removal of hardware – always needs to be combined with systemic antifungal treatment.
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TABLE 12. Recommendations on bone and joint candidiasis
Population Intention Intervention SoR QoE References
Osteomyelitis/spondylodiscitis To cure Surgical debridementa,b C III [147]
Fluconazole 400 mg for 6–12 monthsc A IIu [149]
[148]
[147]
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complex 5 mg/kg for 2–6 weeks followed by fluconazole 400 mg
for 5–11 monthsc
A IIu [149]
[147]
Posaconazole 800 mg for ‡6 weeksc C III [150]
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[158]
[157]
Prosthetic joint infection
with prosthesis retention
To suppress infection Fluconazole 400 mg, life long A III [160]
[161]
[159]
[157]
aIndications for surgery are, for example, instability or large abscess.
bSurgery needs to be combined with antifungal treatment.
cTreat longer if erythrocyte sedimentation rate or C-reactive protein not returned to normal.
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Abstract
Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality.
These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the pre-
vention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin ± Lactobacillus (B-II). The treatment of IC in neo-
nates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system.
Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafun-
gin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated
from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole
(A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for
the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are
extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B
(A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used.
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Introduction
The process of defining therapeutic recommendations in this
document is consistent with paediatric development regula-
tions and guidelines from the European Medicines Agency
(EMA) [1,2]. The EMA has a relatively pragmatic approach to
the licensure of pharmaceutical agents for neonates and chil-
dren. The EMA accepts the requirement for extrapolation of
evidence for efficacy from studies in adults to paediatric
patients, or from older to younger paediatric patients when
the following criteria are met: (i) a medicinal product is to
be used for the same indication(s); (ii) the disease process or
target sensitivity is similar; and (iii) the outcome of therapy is
likely to be comparable [1,2].
Pharmacokinetic studies performed in all the age ranges of
paediatric patients likely to receive a compound, together
with safety studies, may provide adequate information for
use by allowing selection of paediatric doses that will pro-
duce drug exposure similar to those observed in adults. In
situations where the comparability of the disease course or
outcome of therapy is expected to be similar, but the rele-
vant drug exposure in adults is not known, a pharmacokinet-
ics/pharmacodynamics approach combined with safety and
other relevant studies may avoid the need for clinical efficacy
studies [1]. More complex disease–drug combinations may
require specific studies.
The grading scheme used in this manuscript is consistent
with guidelines developed for adults [141]. However, there
are some subtle differences for paediatric patients. The
Expert Group considered three components for grading of
each drug–syndrome combination: (i) evidence for efficacy,
which was frequently, but not invariably, obtained from
studies in adults; (ii) the quality of the pharmacokinetic data
and models performed in either neonates or children that
enable an informed decision about an appropriate regimen
for the specific population; and (iii) specific safety data
obtained in neonates or children that support the use of a
given compound in that specific population. These guidelines
are intended to facilitate optimal antifungal therapy for neo-
nates and children with invasive candidiasis. They are not
necessarily exhaustive. Contraindications, drug–drug interac-
tions and specific warnings for each compound should be
considered by treating physicians. Furthermore, these guide-
lines should be coupled with diagnostic and therapeutic
algorithms tailored to the specific case mix and local fungal
epidemiology of each institution. The incorporation of these
therapeutic guidelines with a risk stratification strategy is
also recommended, especially for prophylaxis and empirical
antifungal therapy.
Overview of syndromes and pathogenesis
of invasive candidiasis in paediatrics
Neonates
Invasive candidiasis (IC) is a common and serious infection in
premature neonates [3]. Invasive candidiasis may present as can-
didaemia, urinary tract infection and involvement of essentially
any other tissue or structure. A syndrome that is particularly
unique to premature infants is haematogenous Candida menin-
goencephalitis (HCME), where there is invasion of the central
nervous system (CNS) by Candida. This syndrome occurs in 15–
20% of cases of IC and may contribute to the increased mortal-
ity and long-term neurodevelopmental abnormalities [3,4].
The risk factors for development of IC in the neonatal
intensive care unit (NICU) include prematurity, central vas-
cular catheterization, abdominal surgery, necrotising entero-
colitis (NEC), exposure to broad-spectrum antibacterial
agents (e.g. third-generation cephalosporins and carbapen-
ems), parenteral nutrition, antacids and endotracheal intuba-
tion. Infants with a smaller gestational age have a higher
incidence of IC (e.g. neonates with gestational age of 23–24,
25–27 and ‡28 weeks have an incidence of 10–20%, 5–10%
and <5%, respectively [5]). Similarly, smaller infants have a
higher incidence of IC (e.g. neonates with birth weight
<750 g, 750–1000 g and >1000 g have an incidence of IC of
>10%, 5–10% and <5%, respectively).
Candida albicans is the most frequent Candida species caus-
ing IC in neonates [6,7]. Candida parapsilosis, Candida tropicalis
and other Candida species are seen less commonly. Unlike
adults, Candida glabrata and Candida krusei are infrequent
causes of IC in the NICU.
Older children
The invasive Candida syndromes in older children closely
resemble those seen in adults. Candida spp. are important
causes of healthcare–associated infections in children and
adolescents with indwelling central venous catheters, in pae-
diatric cancer patients receiving treatment for haematological
malignancies and in paediatric haematopoitic stem cell trans-
plant (HSCT) recipients. Severe sepsis and/or septic shock
occurs in approximately 30% [8,9]; mortality rates range
between 10 and 25% in most series [9] and are close to 50%
in patients admitted to the ICU [8,10,11]. IC is also an
important syndrome in solid organ transplant recipients. The
incidence in this setting remains relatively poorly defined, but
is c. 5–10% in liver, small bowel and pancreas transplantation
[12]. In the individual reports that are available, the incidence
of IC for paediatric heart, lung and liver transplant recipients
is 3.9%, 5% and 19%, respectively [10,13,14].
CMI Hope et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012 39
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 7), 38–52
Prevention of IC in neonates (see Table 1)
General principles
Antifungal prophylaxis may be an appropriate strategy, espe-
cially for the most vulnerable patients (e.g. extremely low-
birth-weight [ELBW] neonates [i.e. <1000 g]). Avoidance of
horizontal transmission in the NICU is paramount and
requires rigorous infection control measures [15]. Treatment
of maternal vaginal candidiasis prior to delivery may prevent
subsequent neonatal colonization [15]. Rational use of
broad-spectrum antibacterial agents (especially third-genera-
tion cephalosporins and carbapenems) and central venous
catheters is probably important, although there is no specific
evidence to support these interventions. The Expert Group
has evaluated three prophylactic strategies for IC in prema-
ture neonates: (i) oral nonabsorbable antifungal agents; (ii)
oral administration of Lactobacillus and lactoferrin; and (iii) i.v.
and oral administration of fluconazole.
Nonabsorbable antifungal agents
Nonabsorbable antifungal agents are used to decrease the
burden of Candida in the gut and therefore the probability of
translocation into the bloodstream. Currently available
agents include nystatin (1 mL suspension, 100 000 U/mL,
every 8 h, during high-risk period) and miconazole oral gel
15 mg Q8 h.
There is a reasonable amount of data that support the use
of nystatin for neonates <1500 g (B-II). This recommendation
is based on randomized controlled trials that have compared
the utility of oral nystatin versus no medication for the pre-
vention of IC [16,17]. A subsequent Cochrane review and
meta-analysis suggest that oral nystatin results in a significant
reduction in IC, but has no impact on mortality [18]. Two
further studies have compared nystatin with fluconazole
[19,20]. While the impact of nystatin on IC is variable (some
studies [16,17,19] suggest that the use of nonabsorbable
agents results in a reduction in colonization and IC [e.g. from
c. 44 to 12% and c. 4–32 to 1.8–6%, respectively, while oth-
ers do not [20]]), there is no impact on mortality, and
longer-term outcomes have not been assessed. A potential
problem with the use of nonabsorbable agents is inadvertent
damage of the very fragile gut epithelium of premature
infants and the subsequent development of necrotizing
enterocolitis (NEC). A grading of B-II reflects the potential
concern for the development of NEC, the absence of an
overall effect on mortality and methodological weaknesses in
these studies.
Miconazole is an alternative nonabsorbable agent for
the prevention of IC in neonates. The only trial that has
examined the utility of miconazole for this indication in neo-
nates suggests that there is a reduction in rectal colonization
by Candida, but no impact upon IC [21]. Given the potential
for the development of triazole resistance that may preclude
the subsequent use of fluconazole, the Expert Group sug-
gests a grading of D-II.
Administration of Lactobacillus and lactoferrin
The administration of Lactobacillus casei subsp. rhamnosus is
intended to prevent the establishment of a microbiological
niche for Candida spp. in the gut. Studies of oral probiotic
administered (106 colony-forming units per day) from the
third day of life until either the end of the sixth week of life
or until discharge from the NICU suggest that this approach
prevents enteric colonization by Candida species, but has no
impact on the overall incidence of IC [22]. Lactoferrin is an
alternative agent that may be effective via the abrogation of
the invasive potential of Candida spp. The administration of
bovine lactoferrin (100 mg/day), alone or in combination
with Lactobacillus rhamnosus GG, significantly reduces the
incidence of late-onset sepsis in very low-birth-weight
(VLBW, <1500 g) neonates, including those episodes attrib-
utable to Candida [23]. Bovine lactoferrin does not affect the
incidence of Candida colonization but reduces the incidence
of IC in VLBW neonates [24]. The Expert Group considers
that lactoferrin alone or in combination with Lactobacillus is
equally reasonable (B-II).
Fluconazole prophylaxis
The use of fluconazole (i.v. or oral) is supported by robust
data that attest to both the efficacy and safety of this agent.
Five RCTs [19,25–28], eight historical control studies [29–
36] and one meta-analysis [37] have examined the utility of
fluconazole for the prevention of IC in neonates. Collec-
tively, all these studies suggest that prophylactic administra-
tion of fluconazole 3–6 mg/kg/dose (i.v. or oral) twice
weekly results in a reduction in Candida colonization and a
91% decrease of IC in neonates <1000 g. While there is a
reduction in mortality, this is not statistically significant (RR
0.74 [CI 0.51–1.09]) [37,38]. Potential theoretical concerns
with the routine use of fluconazole include neurodevelop-
mental toxicity and emergence of drug resistance. Reassur-
ingly, a recent study suggests no toxicity after 8–10 years,
nor the emergence of less susceptible or inherently resistant
Candida species in the NICU [39]. Of note, studies examining
fluconazole prophylaxis were conducted in NICUs with rela-
tively high incidence of IC (e.g. >12%). Most NICUs have an
incidence of IC of <5% for neonates <1000 g, and some <2%
[40]. The potential benefits of fluconazole prophylaxis may
be less with a low incidence of IC.
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The Expert Group recommends that the use of fluconaz-
ole is combined with a risk stratification strategy. Thus,
fluconazole 3–6 mg/kg/dose twice weekly i.v. or orally is
appropriate for all neonates <1000 g in NICUs with rela-
tively high frequency of IC (A-I). For NICUs with a lower
incidence of IC (i.e. <2%), the decision to use the same
fluconazole prophylaxis regimen should be made on a case-
by-case basis and embedded in a risk stratification strategy
(e.g. <1000 g, additional risk factors for IC such as central
venous catheterization, receipt of third-generation cephalo-
sporins or carbapenems) (B-II).
Treatment of IC in neonates (See Table 2)
General principles
Because cultures from deep sites are frequently negative, a
definitive diagnosis of IC in neonates may be problematic [3].
Information on local epidemiology may help guide initial ther-
apy [6]. Any premature infant with microbiological or clinical
evidence of invasive candidiasis should be assumed to have
disseminated disease, and this should prompt a thorough
clinical examination and relevant investigations. In particular,
the possibility of HCME should be considered, and if deemed
probable, antifungal therapy should be designed to treat the
CNS [41]. This important pharmacodynamic difference
between neonates and adults means that the strategy of
combining efficacy data from adults with well-designed PK
studies in neonates may not be appropriate. In this regard,
the Expert Group notes that evidence to support various
compounds in neonatal settings is accrued either from: (i)
case series describing the outcome of drug therapy in neo-
nates or (ii) in vivo to clinical bridging studies. The latter has
been recently applied to the echinocandins.
Amphotericin B formulations
Amphotericin B deoxycholate 1 mg/kg/day can be used for
the treatment of IC in neonates (B-II). This recommendation
is supported by relatively limited clinical data for IC [42] and
HCME [43]. The recommendation is also supported by lim-
ited pharmacokinetic data [44]. There is no specific clinical
information for optimal regimen for the treatment of HCME,
although amphotericin B deoxycholate is effective in a pre-
clinical model of HCME [45]. Liposomal amphotericin B 2.5–
7 mg/kg/day can be used for IC in neonates [46–48] (B-II)
and is safe [49]. While there is no specific clinical informa-
tion for the optimal regimen for HCME, liposomal amphoter-
icin B penetrates the CNS in a preclinical model of HCME
and has antifungal activity in the brain [45]. ABLC 2.5–5 mg/
kg/day i.v. is an alternative agent to both LAmB and DAmB
(C-II). Evidence for efficacy and the population pharmacoki-
netics of ABLC have been described in neonates [50]. Fur-
thermore, preclinical data suggest ABLC is effective for
HCME [45]. The lower grading compared with other ampho-
tericin B formulations reflects continuing uncertainty regard-
ing the use of this agent for IC in general (for both children
and adults) and the relative paucity of clinical data compared
with other formulations.
Triazoles
There are relatively few studies that have specifically exam-
ined the efficacy of fluconazole for neonates. Fluconazole (12
mg/kg with consideration given to a loading dose of 25 mg/kg
although further safety studies are required) can be used to
treat IC in neonates who have not previously received this
agent (B-II). This recommendation is based on data for effi-
cacy and safety in neonates [51–53]. Recent population phar-
macokinetic studies have been used to define an appropriate
regimen [54,55]. There are no preclinical or clinical data that
are available to guide definitive regimens for HCME. Potential
limitations of fluconazole include a relatively narrow spectrum
of antifungal activity compared with other antifungal agents,
and a fungistatic (as opposed to fungicidal) antifungal effect.
Echinocandins
The echinocandins are increasingly used for treatment of IC
in the NICU. The recommendation for micafungin 4–10 mg/
kg/day (B-II) is based on a PK–PD bridging study and detailed
PK studies [56–58]. Micafungin 4 mg/kg approximates drug
exposures achieved in adults. If HCME is thought to be
likely, a higher dosage (e.g. 10 mg/kg) should be used
because of the dose-dependent penetration of micafungin
into the CNS [57]. The Expert Group notes the ‘black box’
warning for micafungin issued by the EMA indicating micafun-
gin should only be used if other agents are not appropriate.
This warning is based upon an increased incidence of hepatic
tumours in rats receiving prolonged dosing of micafungin. To
date, there is no corresponding clinical signal, despite exten-
sive clinical use of micafungin throughout the world. Further-
more, similar studies have not been performed for the other
echinocandins, raising uncertainty as to whether this preclini-
cal finding is a class effect. Preclinical data and PK–PD bridg-
ing studies suggest that an elevated dosage of anidulafungin
may be required to treat HCME [59]. While limited PK is
available [60], further clinical PK studies are required, and
until results from these studies are available, the Expert
Group has not graded anidulafungin for use in this setting.
The currently recommended infant dosage of caspofungin
(25 mg/m2/day) is based on achieving comparable AUCs to
those seen in adults [61]. While clinical efficacy has been
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demonstrated in a small number of case reports and case
series [62–64], there is no evidence that this dosage is nec-
essarily adequate to treat infants with HCME. Moreover, the
use of body surface area as a metric of size may be inaccu-
rate in neonates. For these reasons, and until further data
are available, the Expert Group suggests a grading of C-II is
appropriate.
Prevention and treatment of invasive
candidiasis in children (See Table 3 and 4)
General principles
Primary prophylaxis is a widely accepted strategy for patients
at high risk of developing IC. The underlying incidence of IC
is the most important factor for determining whether pro-
phylaxis is a reasonable strategy, with 10% frequently being
used as a value where the risk–benefit analysis is favourable.
The incidence for patients with acute myeloid leukaemia,
recurrent leukaemia and following allogeneic HSCT is 5–15%
[65–68]. For patients with acute lymphoblastic leukaemia and
solid tumours who are receiving dose-intense chemotherapy
with or without autologous stem cell rescue, the reported
incidence rates are <5% [68,69]. Apart from these general
considerations, the institutional epidemiology is the most
important consideration for designing an appropriate prophy-
lactic regimen.
Prevention of invasive candidiasis in allogeneic HSCT
recipients
Fluconazole (8–12 mg/kg QD i.v. or orally; studied from day
0 to day +75) may be used in allogeneic HSCT recipients (A-
I). This recommendation is based on randomized clinical tri-
als performed in adults who have demonstrated a reduction
in invasive Candida infections [70,71], a persistent survival
benefit in one study [71,72], the existence of paediatric PK
and safety data [73–75], and a paediatric label from the EMA.
Fluconazole should only be used when the risk of invasive
mould infections is suitably low or in combination with a
screening programme for these pathogens.
Itraconazole suspension (2.5 mg/kg Q12h; started after
completion of the conditioning regimen; not approved by
the EMA in patients <18 years of age), which has additional
activity against Aspergillus spp., may also be used for children
‡2 years of age (B-II). The evidence for the use of this
agent for HSCT recipients is derived from randomized clini-
cal trials in adults [76,77] and relatively small paediatric
pharmacokinetic studies [78–80]; the latter is the reason
for the designation of level II evidence. TDM should be per-
formed to verify absorption, compliance and the attainment
of effective and nontoxic concentrations. A trough concen-
tration target of 0.5 mg/L when estimated using HPLC is
reasonable [81,82]. A further option for children aged
‡2 years is voriconazole (day 1: 9mg/kg Q12 h, then 8 mg/
kg Q12h i.v): 9 mg/kg Q12 h PO (max. 350 mg Q12 h) for
2–12 years and 12–14 years with <50 kg; adult dose for
patients 12–14 years >50 kg and for patients >14 years;
studied from day 0 until at least day +100) (A-I). The basis
for this recommendation includes a randomized clinical trial
performed in adults that demonstrates comparable prophy-
lactic efficacy to fluconazole [83] and adequate PK and
safety data [84–89]. An additional consideration is activity
against Aspergillus spp. Prophylactic use of voriconazole
should be coupled with therapeutic drug monitoring; a
trough concentration of ‡1 mg/L is probably a reasonable
target [89–91]. For adults with GVHD and augmented
immunosuppression, posaconazole (200 mg Q8 h) has been
shown to prevent invasive fungal infections, although there
was no effect on overall mortality [92]. Limited data in chil-
dren 13–17 years of age suggest minimal differences in
pharmacokinetics compared with adults [93]. Therefore, po-
saconazole may be appropriate for children who are receiv-
ing immunosuppression for GVHD (B-II). The Expert Group
suggests a lower recommendation than adults because of
relatively rudimentary pharmacokinetic studies in paediatric
patients. If posaconazole is used, therapeutic drug monitor-
ing should be considered, and a trough concentration of
0.7 mg/L after 1-week therapy is a reasonable therapeutic
target [94,95].
Micafungin (1 mg/kg/day i.v. administered from the begin-
ning of the preparative regimen to day +30) may be used
(A-I). This recommendation is based upon robust paediatric
PK [96,97], safety [98], regulatory approval for this indication
and a large randomized clinical trial with inclusion of paediat-
ric patients [99].
Prevention of invasive candidiasis in children with AML and
recurrent leukaemia
The recommendations for patients with AML and/or recur-
rent leukaemia are similar to the allogeneic HSCT setting;
the risk of developing invasive mould disease may be
significant and should be considered [69]. Fluconazole (8–
12 mg/kg/day i.v./orally (max. 400 mg) after the last dose of
chemotherapy and until neutrophil recovery) [100] (A-I)
should only be used when the risk of invasive mould infec-
tions is suitably low or in combination with a screening
programme for these pathogens. Micafungin (1 mg/kg/day
i.v.) is approved for prophylaxis of invasive Candida infec-
tions in patients with profound and prolonged neutropaenia
[ANC <500 for ‡10 days]) [99](A-II). The Expert Group
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suggests level II evidence is appropriate because of the
absence of specific studies in this patient population. Posa-
conazole prevents invasive fungal infections and provides a
survival advantage for patients with AML/MDS compared
with patients receiving fluconazole or itraconazole [101].
Based on limited PK and safety data [93,102], posaconazole
(200 mg Q8 h following completion of chemotherapy until
neutrophil recovery; plus TDM) (B-II) is an option for ado-
lescents >12 years of age.
Further alternatives include the following: (i) itraconazole
(2.5 mg/kg Q12h following chemotherapy with concomitant
TDM; not approved by the EMA for patients <18 years of
age) [103] (B-II); (ii) liposomal amphotericin B (1 mg/kg/every
other day) (B-I) based on studies in adult patients with leu-
kaemia [104] and concomitant paediatric pharmacokinetic
and safety data [105,106]; and (iii) voriconazole (day 1: 9 mg/
kg Q12 h, then 8 mg/kg BID i.v.); 9 mg/kg Q12 h PO (max.:
350 mg Q12 h) for 2–14 years; adult dose for patients
>14 years; plus TDM) [83,107] (A-II). Of note, both micafun-
gin and liposomal amphotericin B may be useful for patients
with acute lymphoblastic leukaemia (ALL) who are receiving
repeat treatments with vincristine and in whom antifungal
triazoles are contraindicated [108].
Prevention of invasive candidiasis in autologous HSCT
recipients and in children with ALL
Patients who have received high-dose chemotherapy with
autologous stem cell rescue (autologous HSCT), who also
have profound and prolonged neutropaenia (ANC <500 for
‡10 days) despite hematopoietic growth factors and/or
severe mucositis, may benefit from primary antifungal pro-
phylaxis [100]. Because the risk of developing invasive mould
TABLE 1. Prevention of invasive candidiasis in neonates
Recommendation and grading Comments References
Oral nystatin, 1 mL 100 000 IU Q8 h (B-II) Reduction in fungal infection, but no change in mortality, potential
gut damage & NEC
[18–20]
Miconazole oral gel 15 mg Q8 h (D-II) Concerns regarding generation of triazole resistance [21]
Lactoferrin 100 mg/day alone or in combination with Lactobacillus
106 colony-forming units per day from the third day of life until
either the end of the sixth week of life or until discharge from
the NICU (B-II)
Reduction in fungal infection by Lactobacillus and lactoferrin [22–24]
Fluconazole 3 or 6 mg/kg 2 times per week iv or orally in ALL
neonates <1000 g in NICUs with high frequency of IC (A-I)
Reduction in Candida colonization, fungal infection, but no change
in overall mortality. Concerns for neurodevelopmental toxicity,
emergence of resistant species
[19,25–37,39]
Fluconazole 3 or 6 mg/kg 2 times per week iv or orally in NICUs
with a lower incidence of IC (i.e. <2%) for neonates:
(a) with birth weight <1000 g,
(b) who have risk factors (i.e. central venous catheters,
third-generation cephalosporins and carbapenems) for the
development of IC (B-II)
Decision for prophylaxis is on an individual basis References as
immediately above
TABLE 2. Therapeutic options for infants with invasive candidiasis and/or HCME
Recommendation and Grading Comments References
Amphotericin B deoxycholate 1 mg/kg/day (B-II) PK in neonates relatively poorly defined, leading to
some uncertainty regarding optimal dosage for
HCME
Clinical trials in adults [123,124]
Pharmacokinetics in neonates [44]
Evidence for efficacy and toxicity [43,135]
Liposomal amphotericin B 2.5–7 mg/kg/day (B-II) PK in neonates remains undefined, leading to some
uncertainty regarding optimal dosage for neonates
The optimal dosage for HCME is not known
Pharmacokinetics in neonates: nil
Evidence for efficacy in neonates [46–48]
Fluconazole
12 mg/kg/day, with consideration given to a loading
dose of 25 mg/kg (B-II)
Relatively limited data for the treatment of IC Evidence for efficacy [51–53]
Pharmacokinetics in neonates: [54,55]
Micafungin 4–10 mg/kg/day i.v. (B-II) The EMA has issued a ‘black box’ warning on the
basis of an elevated incidence of hepatic tumours in
rats receiving prolonged dosing and drug exposures
higher than typically seen in clinical contexts. These
studies have not been performed for other
echinocandins
The currently licensed dosage is 2–4 mg/kg/day. If
HCME is present, preclinical models and PK-PD
bridging studies suggest a higher dosage is required
for effective therapy
Evidence for efficacy derived from preclinical models
[57]
Pharmacokinetics in neonates: [56,58]
Caspofungin
25 mg/m2/day (C-II)
Relatively limited PK and dosing designed to
approximate drug exposure in adults, rather than
HCME
Evidence for efficacy [62–64]
Pharmacokinetics in neonates: [61]
ABLC 2.5–5 mg/kg/day (C-II) The Expert Group rated ABLC ‘C’ because of the
relative paucity of clinical data
The optimal regimen for the treatment of HCME is
not known
Pharmacokinetics in neonates [50]
Preclinical data suggests that ABLC is an effective
agent for the treatment of HCME [45]
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infections is <5% [108], primary options include micafungin
(1 mg/kg QD; studied from the start of high-dose chemo-
therapy until engraftment) [99] (A-I) and fluconazole (8–
12 mg/kg/day i.v./orally (max. 400 mg) (A-I) [100]. Alternative
options include itraconazole (2.5 mg/kg Q12h with TDM; not
approved in subjects <18 years of age) [103] (B-II) and
liposomal amphotericin B 1 mg/kg/every other day i.v. (B-I)
based on data derived from adult patients leukaemia [104].
TABLE 3. Primary prophylaxis of invasive candidiasis in children
Clinical Context Recommendation and Grading Comments References
Allogeneic HSCT Fluconazole 8–12 mg/kg QD i.v. or orally;
studied from day 0 until day +75
post transplant (A-I)
Fluconazole should only be used if the
institutional incidence of invasive mould
infections is low, or if there are active
diagnostic and therapeutic algorithms for mould
infections
Clinical trials in adults [70–72]
PK studies in children [73]
Safety and efficacy in children [74,75]
Allogeneic HSCT Micafungin 1 mg/kg QD i.v.; studied from
the start of the preparative regimen until
day +30 (A-I)
Spectrum of antifungal activity also extends to
Aspergillus spp.
Clinical trials in adults with inclusion of
paediatric patients [99]
PK studies in children: [96,97]
Safety and efficacy in children [98]
Allogeneic HSCT Voriconazole 8 mg/kg BID (day 1: 9 mg/kg
BID) for i.v., and 9 mg/kg BID for oral
administration (max.: 350 mg BID) for the
ages of 2–14 years and the approved adult
dose for patients 15 years and older and
12-14 year olds weighing >50 kg; studied
from day 0 until at least day +100 (A-I)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
TDM should be performed; dosing target/ trough
concentration of ‡1 mg/L
Clinical trials in adults [83]
PK studies in children: [84–88]
TDM dosing target: [89–91]
Safety/efficacy in children: [84–89,136–138]
Allogeneic HSCT Itraconazole suspension 2.5 mg/kg Q12 h
for patients ‡2 years of age; to be started
after completion of the conditioning
regimen; studied until at least day +100
(B-II)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
Not approved in patients <18 years
TDM is suggested; dosing target: trough
concentration of ‡0.5 mg/L
Clinical trials in adults: [76,77]
PK studies in children [78–80]
TDM dosing target [81,82]
Safety/efficacy in children [79]
Allogeneic HSCT Posaconazole suspension 200 mg Q8 h
orally for patients with ‡ grade II GVHD
and ‡13 years of age (B-II)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
Not approved in patients <18 years
TDM is suggested; dosing target: trough
concentration of ‡0.7 mg/L
Clinical trials in adults: [92]
PK studies in children: [93]
TDM dosing target [94]
Safety/efficacy in children: nil
AML and recurrent
leukaemia
Fluconazole 8–12 mg/kg i.v. or orally after
last dose of chemotherapy until neutrophil
recovery (A-I)
Fluconazole should only be used if the
institutional incidence of invasive mould
infections is low, or with an active diagnostic
and therapeutic algorithms for clinical signs and
symptoms suggestive of these infections
Clinical trials in adults [100]
PK studies in children [73]
Safety/efficacy in children: [74,75]
AML and recurrent
leukaemia
Micafungin 1 mg/kg QD i.v.; after last dose
of chemotherapy until neutrophil recovery
(A-II)
Prophylactic efficacy inferred from study in
HSCT patients
Alternative for patients with leukaemia receiving
vincristine
As above
AML and recurrent
leukaemia
Itraconazole suspension 2.5 mg/kg Q12 h
for patients ‡2 years of age; after last dose
of chemotherapy until neutrophil recovery
(B-II)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
Not approved in patients <18 years
TDM is suggested; dosing target: trough
concentration of ‡ 0.5 mg/L
Clinical trials in adults [103]
PK studies in children: [78–80]
TDM dosing target: [81,82]
Safety/efficacy in children [79]
AML and recurrent
leukaemia
Liposomal amphotericin B 1 mg/kg QOD i.v.
(B-I)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
Alternative antifungal agent for patients with
leukaemia receiving vincristine
Clinical trials in adults [104]
PK studies in children [105]
Safety/efficacy in children [106]
AML and recurrent
leukaemia
Voriconazole 8 mg/kg BID (day 1: 9 mg/kg
BID) for i.v., and 9 mg/kg BID for oral
administration (max.: 350 mg BID) for the
ages of 2–14 years and the approved adult
dose for patients 15 years and older and
12-14 year olds weighing >50 kg; after last
dose of chemotherapy until neutrophil
recovery (B-I)
As above As above
AML and recurrent
leukaemia
Posaconazole 200 mg TID orally for patients
‡13 years of age; after last dose of
chemotherapy until neutrophil recovery
(B-II)
As above As above
Autologous HSCT Fluconazole 8–12 mg/kg i.v. or orally after
last dose of chemotherapy until neutrophil
recovery (A-I)
Patients with expected profound and prolonged
neutropaenia (ANC <500 ‡ 10 days) despite
use of growth factors and/or severe mucositis
may benefit from antifungal prophylaxis
References as above
Autologous HSCT Micafungin 1 mg/kg QD i.v.; after last dose
of chemotherapy until neutrophil recovery
(A-I)
As above References as above
Autologous HSCT Itraconazole suspension 2.5 mg/kg Q12 h
for patients ‡2 years of age; after last dose
of chemotherapy until neutrophil recovery
(B-II)
As above References as above
Autologous HSCT Liposomal amphotericin B 1 mg/kg QOD i.v.
(B-I)
As above References as above
HSCT, haematopoietic stem cell transplantation; PK, pharmacokinetics; TDM, therapeutic drug monitoring.
Note that individual ALL patients exhibiting prolonged and profound neutropaenia (ANC <500 for ‡10 days) and receiving high doses of glucocorticosteroids may benefit
from antifungal prophylaxis [68]. As these risk factors are shared by opportunistic moulds, a mould active agent is preferred (CIII).
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While no general recommendation can be made for de
novo acute lymphoblastic leukaemia, individual patients
exhibiting prolonged and profound neutropaenia (ANC <500
for ‡10 days) and receiving high doses of corticosteroids
may benefit from antifungal prophylaxis [68]; because these
risk factors are shared by opportunistic moulds, a mould
active agent is preferred (CIII).
Prevention of invasive candidiasis in solid organ transplant
recipients and critically Ill nonneutropaenic children
Because robust data on epidemiology and risk factors are
absent, firm recommendations for the prevention of IC are
somewhat difficult. The most appropriate agent depends on
the underlying incidence of invasive aspergillosis, which in
turn is a function of the transplant type and institutional inci-
dence of mould infections. If the incidence of invasive asper-
gillosis is suitably low, then fluconazole 8–12 mg/kg/day i.v.
or orally is reasonable in the majority of cases (recommen-
dation not rated).
Similar uncertainties exist for critically ill nonneutropaenic
children in the paediatric intensive care unit (PICU). While no
evidence-based recommendations can be made, fluconazole 8–
12 mg/kg/day i.v. or orally is a reasonable option for the pre-
vention of invasive candidiasis in critically ill nonneutropaenic
children in the intensive care unit, especially in cases of exten-
sive abdominal surgery (recommendation not rated).
Secondary Prophylaxis
Secondary chemoprophylaxis, as a term, is ill-defined for
invasive candidiasis and may overlap with continued treat-
ment or maintenance treatment in chronic disseminated
candidiasis with an agent that has proven efficacy against
Candida spp. [109]. Similar to adults, secondary chemopro-
phylaxis is not indicated in case of prior uncomplicated can-
didaemia without any sign of deep seated infection –
including situations in which the patient is exposed to a
new immunosuppressive condition such as prolonged neu-
tropaenia induced by chemotherapy, autologous or alloge-
neic HSCT (CIII).
Empirical and pre-emptive antifungal therapy
Empirical antifungal therapy is considered by many experts a
standard of care in haemato-oncological patients with pro-
longed neutropaenia (ANC <500 for ‡10 days) and refrac-
tory or new fever, despite broad-spectrum empirical
antibacterial therapy. It may provide targeted prevention in a
high-risk situation and early treatment of yet occult infec-
tions. Based on large randomized clinical trials with inclusion
and separate analysis of paediatric patients [110–113], ade-
quate paediatric PK and safety data, recommended options
in paediatric patients of all age groups include liposomal
amphotericin B (1–3 mg/kg QD) (A-I) and caspofungin (load-
ing dose 70 mg/m2/day, followed by 50 mg/m2/day. Option
TABLE 4. Treatment of invasive candidiasis in children
Recommendation and Grading Comments References
Amphotericin B deoxycholate 0.6–1 mg/kg/
day (C-I)
Lipid preparations of amphotericin B have a more
favourable toxicity profile
Issues related to supply in some European countries
Clinical trials in adults [123,124]
PK studies in children [132]
Evidence for safety and efficacy in children with invasive
candidiasis: Nil
Liposomal amphotericin B 3 mg/kg/day (A-I) Clinical trials in adults and children [48,127]
PK studies in children [105]
Safety in children [48]
Fluconazole
8–12 mg/kg/day (B-I)
Fungistatic antifungal activity Evidence for efficacy in adults [123,139]
PK studies in children [73]
Evidence for safety and efficacy in children [75]
Voriconazole (day 1: 9 mg/kg Q12h, then
8 mg/kg BID i.v.); and 9 mg/kg BID for oral
administration (max.: 350 mg BID) for the
ages of 2–14 years and the approved adult
dose for patients 15 years and older and
12–14 year olds weighing >50 kg; after last
dose of chemotherapy until neutrophil
recovery (B-I)
Fungistatic antifungal activity
Spectrum extends to Candida glabrata and Candida krusei
TDM should be considered
Evidence for efficacy in adults [134]
PK studies in children: [84–88]
TDM dosing target: [89–91]
Micafungin
<40 kg 2–4 mg/kg (A-I)
Well conducted PK trials to define dosages that lead to
comparable drug exposures in children
The EMA has issued a ‘black box’ warning on the basis of
an elevated incidence of hepatic tumours in rats
receiving prolonged dosing and drug exposures higher
than typically seen in clinical contexts.
Efficacy established in clinical trials in children and
adults [48,127]
PK studies in children: [96,97]
Safety/efficacy in children [98]
Anidulafungin
3 mg/kg as a single loading dose followed by
1.5 mg/kg/day (B-II)
Some uncertainty about optimal paediatric regimen
because of relatively limited PK data
No data for efficacy and safety in children
Evidence for efficacy in adults [128]
PK studies in children [129]
Caspofungin
Loading dose 70 mg/m2/day, followed by
50 mg/m2/day. Option to increase to
70 mg/m2/day if clinically indicated,
maximum absolute dose of 70 mg/day (A-I)
Evidence for efficacy in adults [124]
PK studies in children [125]
Evidence for safety in children [126]
Amphotericin B Lipid Complex (B-II) Relatively limited clinical data for efficacy and safety
No PK data for children
Evidence for efficacy and safety [131,140]
PK in children: nil
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to increase to 70 mg/m2/day if clinically indicated with a max-
imum dose of 70 mg/day) (A-I). Of note, incidence and
extent of nephrotoxicity of liposomal amphotericin B in chil-
dren appears to be lower than in adults, hence the higher
rating compared with adults. Fluconazole may be used if the
incidence of invasive aspergillosis is low or if a mould-specific
diagnostic algorithm is being used (B-II) [114]. Amphotericin
B deoxycholate 0.7–0.8 mg/kg/day may be reasonable if this
compound is available, and the higher toxicity is tolerable
from a clinical perspective (B-II).
Empirical therapy in adult ICU patients has been shown to
be of no benefit when using a fever criterion [115], but no
data exist for nonneonatal paediatric patients. While several
studies in adult ICU patients show potential utility of scoring
systems as the basis for pre-emptive treatment of invasive
candidiasis (see for example [116–120]), no data exist in
other populations and in paediatric patients, and therefore,
no recommendations are made.
Treatment of invasive candidiasis and
candidaemia in children
General principles
Many of the general principles pertinent to the management of
invasive candidiasis in children are derived from adults, and
these are as follows: (i) antifungal therapy should be adminis-
tered as quickly as possible (extrapolated from [121,122]); (ii)
the optimal duration of therapy is 14 days after blood cultures
are sterile, provided there is no unresolved deep infection or a
severe persistent underlying immunological deficit (extrapo-
lated from [123]); (iii) the appropriate choice of an anti-Can-
dida agent may be influenced by local epidemiology because of
the reduced susceptibility or resistance of some species to
certain antifungal classes/agents; (iv) clinical evaluation for deep
sites of infection, including an ophthalmological examination is
required in all cases of candidaemia; (v) consideration should
be given to removing or at least replacing intravenous cathe-
ters and/or other implanted prosthetic devices in a timely
manner; and (vi) there is no firm recommendation regarding
combination antifungal chemotherapy, but this may be consid-
ered in some situations (e.g. severe life-threatening infection,
compromised drug penetration (e.g. cases of CNS infection,
osteomyelitis, complicated urinary tract infections and compli-
cated intra-abdominal infections).
Echinocandins
The echinocandins are first-line agents for the treatment of IC
in children. The Expert Group does not consider that there
are significant microbiological nor pharmacological differences
between caspofungin, micafungin and anidulafungin. Differences
in recommendations reflect the different stages in the develop-
ment of these compounds for paediatric patients. Caspofungin
(70 mg/m2 loading dose followed by 50 mg/m2/day i.v.) can be
used for the treatment of IC (A-I). This recommendation is
based on established efficacy in adults, a well-designed PK
study [124,125], documented safety [126] and the existence of
a paediatric label from the EMA. Similarly, micafungin (2–4 mg/
kg/day i.v.) can also be used (A-I); this recommendation is
based on a randomized control trial in adults and children
[48,127], extensive pharmacokinetics [96,97], safety data [98]
and the existence of a paediatric label. Anidulafungin (3 mg/kg
loading dose, followed by 1.5 mg/day) is an alternative agent
(B-II). While there is a RCT in adults [128] and some paediatric
PK data [129], the Expert Group suggests a lower level recom-
mendation for children because of uncertainty regarding the
optimal paediatric dosage and relatively limited paediatric
safety data. The Expert Group anticipates an ‘upgrading’ of ani-
dulafungin with further clinical and PK studies and future regu-
latory approval for use in paediatric patients.
Amphotericin B formulations
Liposomal amphotericin B 3 mg/kg/day is an alternative first-
line agent (A-I). This is based on a RCT in adults and chil-
dren, concomitant pharmacokinetic studies [48,105,106,127]
and safety data in children [48]. A higher rating compared
with adults (i.e. B-I) is based on the lower incidence of toxic-
ity in children [48,106]. ABLC is an alternative agent for IC,
and there is some clinical experience in children [130,131].
Because of an absence of pharmacokinetic studies, and some
uncertainty regarding the optimal regimen for invasive candi-
diasis, the Expert Group rated this agent B-II. Amphotericin
B deoxycholate 0.6–1 mg/kg can be used for IC (C-I). This
recommendation is supported by clinical data from adults
[123,124] and concomitant PK data for children [132,133].
Amphotericin B deoxycholate is graded lower than lipid
preparations principally because of a less favourable toxicity
profile. Nevertheless, the Expert Group recognizes the use
of amphotericin B deoxycholate for treatment of IC may be
appropriate if other amphotericin B formulations are not
available and also recognize a different grading compared
with adults.
Triazoles
The triazoles have been widely used for treatment of inva-
sive candidiasis in children. The use of fluconazole 8–12 mg/
kg/day i.v. [B-I] is based on extensive RCT data in adults and
paediatric PK studies [73,123,124,128] and extensive safety
data [75]. The lower rating than suggested for prophylaxis
reflects a fungistatic mode of activity. Nevertheless, fluconaz-
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ole may be a reasonable initial choice for children with
IC who are haemodynamically stable and if there is a low
institutional incidence of less susceptible or frankly resistant
Candida species. There is some uncertainty regarding the use
of fluconazole for Candida glabrata infections because this
organism tends to exhibit higher MICs. Candida krusei is
intrinsically resistant to fluconazole, and this agent should
not be used in this context. Voriconazole (day 1: 9 mg/kg
Q12 h, then 8 mg/kg BID i.v.); 9 mg/kg Q12 h PO (max.
350 mg Q12 h) for 2–12 years and 12–14 years with <50 kg;
adult dose for patients 12–14 years >50 kg and patients
>14 years) can be used for IC. A recommendation of B-I is
based on a RCT in adults coupled with several well-designed
PK studies in children [84–89,134]. Therapeutic drug moni-
toring should be performed. The ‘B’ rating reflects the fungi-
static pattern of killing that appears common to the
triazoles. Voriconazole is more potent in vitro against Candida
glabrata than fluconazole and has activity against Candida kru-
sei and may be a reasonable choice for these infections.
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Abstract
Fungal diseases still play a major role in morbidity and mortality in patients with haematological malignancies, including those undergoing hae-
matopoietic stem cell transplantation. Although Aspergillus and other filamentous fungal diseases remain a major concern, Candida infections are
still a major cause of mortality. This part of the ESCMID guidelines focuses on this patient population and reviews pertaining to prophylaxis,
empirical/pre-emptive and targeted therapy of Candida diseases. Anti-Candida prophylaxis is only recommended for patients receiving allogeneic
stem cell transplantation. The authors recognize that the recommendations would have most likely been different if the purpose would have
been prevention of all fungal infections (e.g. aspergillosis). In targeted treatment of candidaemia, recommendations for treatment are available
for all echinocandins, that is anidulafungin (AI), caspofungin (AI) and micafungin (AI), although a warning for resistance is expressed. Liposomal
amphotericin B received a BI recommendation due to higher number of reported adverse events in the trials. Amphotericin B deoxycholate
should not be used (DII); and fluconazole was rated CI because of a change in epidemiology in some areas in Europe. Removal of central venous
catheters is recommended during candidaemia but if catheter retention is a clinical necessity, treatment with an echinocandin is an option (CIIt).
In chronic disseminated candidiasis therapy, recommendations are liposomal amphotericin B for 8 weeks (AIII), fluconazole for >3 months or
other azoles (BIII). Granulocyte transfusions are only an option in desperate cases of patients with Candida disease and neutropenia (CIII).
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Introduction
Infectious complications remain a major obstacle in the suc-
cessful treatment of patients with malignant diseases. This
part of the ESCMID guidelines focuses on the special need of
this patient population with malignancies that had received
chemotherapy or radiotherapy. Candida diseases played a piv-
otal role in the past in patients with malignancies [1–3]. In an
Italian study, patients with AML and ALL developed candida-
emia at incidence rates of 2–3% and 4–5%, respectively [4].
In one German hospital, candidaemia remains a disease with
a high fatality rate [5]. Studies report an overall mortality
risk as high as 38% with an attributable mortality of 19% [2].
Risk factors such as previous triazole exposure, age, high AP-
ACHEII scores, renal failure and neutropenia contribute to
these high mortality rates [2,6]. A change in the Candida spe-
cies epidemiology also needs special attention since fluconaz-
ole sensitive C. albicans is not the sole cause of disease [2,7].
Therefore, Candida diseases deserve special attention in this
high-risk population. We included recommendations for hae-
matopoietic stem cell transplant recipients, which is an inte-
gral part of the guideline. This guideline is divided into four
parts: prophylaxis, pre-emptive/empirical therapy strategies,
targeted treatment and specific situations in patients with
malignancies.
Numerous guidelines have been published to date and
have usually included all fungal diseases [8–11]. Here, we
focus on Candida diseases with diagnostic procedures
and recommendations for treatment. This guideline was
originally edited as described previously by the first 4
authors and later reviewed and edited by the entire
EFISG (ESCMID Fungal Infection Study Group) guideline
group [155].
Other fungal diseases, for example aspergillosis in this
patient population will also need special attention. The
authors recognize that other filamentous fungal infections
besides aspergillosis play a more pivotal role in the morbid-
ity and mortality in this patient population (e.g. agents of
mucormycosis) [12–16]. Therefore, the recommendations
for prophylaxis and empirical/pre-emptive therapy would
possibly direct our guideline recommendation in a different
direction because this guideline focuses solely on Candida
diseases.
The same grading system for the strength of recommen-
dation and its documented quality of evidence are used
throughout of this guideline as in the majority of the EFISG
guidelines. The explanations and abbreviations used in this
document are given in Table 1.
Anti-Candida prophylaxis in allogeneic
haematopoietic stem cell transplantation
The intention of the EFISG recommendations for prophylaxis
in allogeneic haematopoietic stem cell transplantation is to
look at the possibility of reducing morbidity and mortality
due to Candida diseases. Obviously, the authors recognize
that the recommendations would have been significantly dif-
ferent if the purpose would have been prevention of all fun-
gal infections (e.g. aspergillosis). The prescribing physician
should be aware of these interpretations. Different immune
deficient situations, often referred to as the ‘net state of
immunosuppression’, need to be appreciated during the
course of allogeneic haematopoietic stem cell transplantation
[17]. During the early post-transplantation phase, neutrope-
nia is a major finding in these patients. Criteria for selecting
prophylaxis throughout the various phases after transplanta-
tion should be a low toxicity profile and good efficacy. For
the purpose of reducing morbidity, various antifungal agents
have similar outcomes as fluconazole and have therefore
received a similarly strong recommendation. But the strength
of recommendation by the EFISG when including all possible
fungal infections (i.e. aspergillosis) would be most likely dif-
ferent.
For prevention during the early neutropenic phase after
transplantation, almost all available azoles are scored as
highly recommended. Indeed, several publications demon-
strated a reduction in morbidity for Candida diseases [18–
23]. Later studies utilized voriconazole in comparison with
itraconazole or fluconazole as comparators [24,25]. Despite
TABLE 1. Strength of the EFISG Recommendation and
Quality of Evidence. Two parts: Strength of a
Recommendation (SoR) and Quality of Evidence (QoE)
Strength of a recommendation
Grade A ESCMID strongly supports a recommendation for use
Grade B ESCMID moderately supports a recommendation for use
Grade C ESCMID marginally supports a recommendation for use
Grade D ESCMID supports a recommendation against use
Quality of Evidence
Level I Evidence from at least one properly designed randomized,
controlled trial
Level II* Evidence from at least one well-designed clinical trial, without
randomization; from cohort or case-controlled analytic
studies (preferably from >1 centre); from multiple time
series; or from dramatic results of uncontrolled experiments
Level III Evidence from opinions of respected authorities, based on
clinical experience, descriptive case studies, or reports of
expert committees
*Added index:
r: Meta-analysis or systematic review of randomised controlled trials.
t: Transferred evidence that is results from different patients’ cohorts, or similar
immune-status situation.
h: Comparator group is a historical control.
u: Uncontrolled trial.
a: Published abstract (presented at an international symposium or meeting).
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the absence of noninferiority testing in the recent voriconaz-
ole trials, an equal outcome compared with fluconazole is
assumed and therefore voriconazole received an AI recom-
mendation for the prevention of Candida disease. Posaconaz-
ole was not tested in a trial during the early phase of
allogeneic haematopoietic stem cell transplantation but the
duration and severity of neutropenia is very similar to that
observed during induction chemotherapy for AML therapy
[26]. Because of this implied evidence, posaconazole received
an AIIt recommendation. Micafungin and caspofungin were
the only echinocandins so far assessed in prophylaxis and
demonstrated similar efficacy to fluconazole in transplant
recipients [27]. Chou et al. used caspofungin in allogeneic
stem cell recipients. In this retrospective study, 7.3% of the
123 patients developed a fungal disease. Two of the nine
cases with fungal disease were Candida tropicalis and Candida
glabrata infections [28].
In addition to the early neutropenic phase, another time
period plays historically an important role after allogeneic ha-
ematopoietic stem cell transplantation, that is, the first
100 days after transplantation. During this period, patients
are also prone to fungal diseases but not all antifungal agents
(e.g. micafungin and posaconazole) have been tested during
this period [27]. Historically, a few azoles were able to
reduce morbidity and mortality, especially fungal-attributable
mortality, during this phase [18,19]. However, other trials
examined the value of prophylaxis beyond the neutropenic
phase to include this first 100 days period. As for the vorico-
nazole prophylaxis trial that was performed during the first
100 days after transplantation, it had a similar outcome to
fluconazole [24]. Therefore, the AI recommendation with
the intention to reduce morbidity in invasive candidiasis is
ascribed to voriconazole and fluconazole. In the well-known
trials by Goodman et al. [18] and Slavin et al. [19], survival
advantage was driven by reduced mortality to Candida dis-
ease. In the trial performed by Marr et al. [22], itraconazole
demonstrated superiority to fluconazole but no mortality dif-
ference was noted. Itraconazole was associated with signifi-
cantly more toxicity and this explains a weaker strength of
recommendation for itraconazole than fluconazole. It
remains unclear whether patients without GVHD and recov-
ered neutrophils need anti-Candida prophylaxis during the
first 100 days after transplantation.
Another important intention for the outcome of patient
care is the survival advantage when using antifungal agents as
prophylaxis. Again, during the early phase of neutropenia, all
azoles except fluconazole received a lower recommendation
(C). During the first 100 days after transplantation, only
fluconazole compared with placebo was able to demonstrate
a survival advantage in Candida diseases [18,19]. Both vorico-
nazole trials did not demonstrate any mortality difference
[24,25]. The overall death rate in the Cornely et al. [26] trial
was significantly lower in patients with posaconazole, and
therefore, posaconazole received a slightly stronger grade of
recommendation. Finally, during moderate to severe graft-
versus-host disease, posaconazole received a weaker BI rec-
ommendation. In the Ullmann et al. [29] trial, posaconazole
had an identical outcome regarding Candida infection com-
pared with fluconazole, but the rate of fungal-related death
was lower with posaconazole and consequently posaconazole
received a slightly higher recommendation, although the Can-
dida-associated death rate was not clear. The association
between intention and the dosage of the intervention, includ-
ing strength of recommendation, are noted in Table 2.
Another important scenario of immunosuppression plays a
significant role in the outcome in the transplant recipient.
Due to increased immunosuppressive therapy during the lat-
ter phase (beyond 100 days) in patients with graft-versus-
host disease, slow T-cell recovery and increased risk of fun-
gal infections is obvious. The trial by Ullmann et al. [29] dem-
onstrated that posaconazole and fluconazole were equally
efficacious in preventing candida infections. Other drugs
were rated weaker (Table 2). Itraconazole and amphotericin
B deoxycholate received a weaker recommendation because
of a weaker safety profile [22,30–32].
Anti-Candida prophylaxis in autologous
haematopoietic stem cell transplantation
and in severe and prolonged neutropenia
In the autologous transplant setting, only the neutropenic
phase can be considered a possible risk situation for Candida
diseases. But with the improvement of autologous transplan-
tation procedures over time, antifungal prophylaxis is not rec-
ommended for autologous transplantation recipients [33].
Nevertheless, in centres with a high incidence of Candida dis-
ease, prophylaxis could remain an option, but based on recent
data only a weak C recommendation is provided for itraco-
nazole and posaconazole (C) [26,34]. The group was not able
to provide a recommendation when antibody treatment is co-
administered (e.g. rituximab) due to the lack of data, and obvi-
ously, there seems to be no increased risk of fungal infections.
There is indirect evidence for a survival advantage in prophy-
laxis for invasive candida disease, which is only available from
the Cornely et al. [26] trial for patients with severe and pro-
longed neutropenia. None were studied with other drugs for
Candida disease in autologous stem cell recipients. In general,
autologous haematopoietic stem cell transplantation is not
considered a high-risk situation for patients.
CMI Ullmann et al. Guideline for the management of Candida diseases in haematological malignancies and HSCT 2012 55
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 7), 53–67
The treatment of numerous other malignant diseases
causes neutropenia in varying degrees of severity and dura-
tion. Prophylaxis in this patient population is usually adminis-
tered only if the patient develops profound and prolonged
neutropenia. Again, our group does not support prophylaxis
for the prevention of Candida diseases in this setting (pro-
phylaxis: DII).
In nontransplantat settings, all recommendations are very
similar to those for autologous transplantation. There is only
very weak evidence for the use of azole prophylaxis against
Candida diseases for the group of azoles. The study by
Glasmacher et al. [32] saw no difference between fluconazole
and itraconazole. Another randomized placebo-controlled
study demonstrated the superiority of itraconazole for
TABLE 2. Anti-Candida prophylaxis for allogeneic haematopoietic stem cell recipients
Intention: Morbidity
reduction
Intention: Survival
improvement
ReferencesSoR QoE SoR QoE
Intervention (anti-Candidal prophylaxis) during the neutropenic phase
Fluconazole 400 mg qd if no prophylaxis is considered A I A I [18–20,22,23]
Itraconazole* 2.5 mg/kg oral solution tid B I C I [22,23]
Posaconazole* 200 mg tid A IIt B IIt [26,29]
Voriconazole* 200 mg bid A I C I [24]
Caspofungin* 70/50 mg qd C IIu C III [28]
Micafungin* 50 mg qd A I C I [27]
Anidulafungin NR ND NR ND
Liposomal amphotericin B 50 mg every other day iv, 100 mg/weekly B II C III [38,39]
Intervention (anti-Candidal prophylaxis) during the first 100 days without GVHD and neutrophil recovery
Fluconazole 400 mg qd A I A I [18–20,22,23]
Itraconazole* 2.5 mg/kg oral solution tid B I C I [22,23]
Posaconazole* 200 mg tid C III C III [26,29]
Voriconazole* 200 mg bid A I C I [24]
Caspofungin* 70/50 mg qd C IIu C IIu [28]
Micafungin* 50 mg C III C III [27]
Anidulafungin NR ND NR ND
Liposomal amphotericin B 50 mg every other day iv, 100 mg/weekly C III C III [38,39]
Intervention (anti-Candidal prophylaxis) in GVHD
Fluconazole 400 mg qd A I C I [18–20,22,23]
Itraconazole* 2.5 mg/kg oral solution tid C I C I [22,23]
Posaconazole* 200 mg tid A I B I [29], equal outcome
regarding Candida
disease
Voriconazole* 200 mg bid B I C I [24] equal outcome
regarding Candida
disease
others NR ND NR ND ND
NR, no recommendation; ND, no data available.
*Decision was based on comparative trials with fluconazole.
TABLE 3. Anti-Candida prophylaxis outside of allogeneic haematopoietic stem cell transplantation (e.g. autologous
haematopoietic stem cell transplantation or chemotherapy induced neutropenia)
Intention Situation
Autologous HCT Severe and prolonged neutropenia
ReferencesIntervention SoR/QoE Intervention SoR/QoE
Reduce morbidity and
mortality (during and
after high dose
chemotherapy)
Any prophylaxis DIII Any prophylaxis DIII [33]
Additional antibody
treatment (e.g.
retuximab)
Any prophylaxis DIII Any prophylaxis DIII
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Fluconazole ND Fluconazole CI For autologous
HCT: [26, 34]
For neutropenia:
[26, 32, 35-38, 40–43]
Itraconazole CII Itraconazole CI
Posaconazole CIIt Posaconazole CIIt
Voriconazole ND Voriconazole ND
Anidulafungin ND Anidulafungin ND
Caspofungin ND Caspofungin CI
Micafungin ND Micafungin ND
Nystatin DIIt Nystatin DII
Any amphotericin
B formulation
ND Any amphotericin
B formulation
DI
*If an institution wishes prophylaxis, weak recommendations for selected antifungal agents are provided.
ND, no data.
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preventing superficial fungal infection in patients with haema-
tological malignancies and neutropenia [35]. Only one study
by Menichetti et al. [36] demonstrated a significant lower
incidence of fungaemia due to Candida species in 0.5% of itr-
aconazole recipients and in 4% of placebo recipients, a differ-
ence of 3.5 percentage points (95% CI, 0.5–6%; p <0.01).
Obviously, no overall survival advantage in Candida-associated
mortality was noted.[36,37] In the trial by Penack et al. [38],
low dose of liposomal amphotericin B did not significantly
prevent Candida infections. In a similar but smaller trial by
Cordonnier et al. [39], only one of twenty-nine patients
developed probable Candida disease. Other trials utilized var-
ious comparators (e.g. amphotericin B/nystatin or fluconazole
vs. itraconazole), but none demonstrated superiority [40,41].
Nystatin, an oral polyene, cannot be recommended as pro-
phylaxis [42]. Only one retrospective trial where micafungin
was assessed as prophylaxis led to a significant decrease in
the occurrence of IFI (from 12.3% to 1.5%, p 0.001) [43]
(Table 3).
Secondary prophylaxis is not indicated in cases of prior
candidaemia without any sign of deep-seated infection when
patients are exposed to a new immunosuppressive therapy
or where prolonged neutropenia is induced by chemother-
apy, autologous or allogeneic HCT. The strength of recom-
mendation for secondary prophylaxis in patients with a
history of deep-seated invasive Candida disease (not candida-
emia alone) was rated C III.
Empiric or pre-emptive (diagnostic driven)
antifungal therapy
In patients expected to suffer prolonged duration of neutro-
penia [>10 days] (induction and consolidation chemotherapy
of AML/MDS and autologous, or allogeneic transplantation)
fever occurs frequently and is usually treated primarily with
broad-spectrum antibacterial agents. If the patient does not
defervesce after at least 3–4 days of antibacterial treatment,
the presence of an undetected fungal infection is assumed
and antifungal therapy is usually added with the intention of
preventing further morbidity or death (AII) [44]. Extensive
diagnostic workup is required to exclude a clinically or
mycological documented infection which might require spe-
cific therapy.
Again, similar to the prophylactic indication, a challenge in
providing recommendations was the fact that empirical treat-
ment is not only given for the intention of treating as early
as possible an undetected Candida disease, but also any kind
of fungal infection (e.g. filamentous fungal infections). With
regards to a reduction in morbidity, liposomal amphotericin
B and caspofungin received an AI recommendation [44–47]
(Table 4). Voriconazole failed to demonstrate noninferiority
when compared to liposomal amphotericin B but in a subset
analysis of high-risk patients no differences were noted [48].
In a prospective but one-armed trial with micafungin, not a
single patient receiving empiric treatment developed a break-
through fungal infection [49]. In a retrospective trial compar-
ing micafungin and caspofungin, breakthrough Candida
diseases were detected at a rate of 0.7% and 2.8%, respec-
tively [50]. Amphotericin B deoxycholate and fluconazole
were not recommended for empirical treatment despite the
existence of adequate studies in the past, because of toxicity
in the first case, and narrow spectrum of action in the sec-
ond case [51–53]. The differences in the grading of ampho-
tericin B formulations lie solely in the different toxicity
profiles [54–56]. Amphotericin B colloidal dispersion causes
infusion-related events similar in frequency and intensity to
amphotericin B deoxycholate and in a direct double-blind
comparison trial amphotericin B lipid complex was more
toxic than liposomal amphotericin B [54,55]. The use of itr-
aconazole provided some promising results in a noncompara-
tor trial and in a recent published trial compared with
amphotericin B [56,57]. In the latter trial, itraconazole had a
better outcome. The major limitation for fluconazole was
TABLE 4. Empiric therapy to treat possible Candida disease: All situations causing severe and prolonged neutropenia
Intention Intervention
Allogeneic
HCT included SoR QoE References
Morbidity reduction Liposomal amphotericin B (3 mg/kg/day) Yes A I [44,45,47,55]
Caspofungin (70 mg on day 1 then 50 mg) Yes A I [46,47]
Amphotericin B colloidal dispersion (4 mg/kg/day) Yes C I [54]
Amphotericin B lipid complex (5 mg/kg/day) Yes B I [55]
Itraconazole (200 mg iv q12h on day 1 & 2 then 200 mg iv/day) ND B I [56,57]
Voriconazole (2 · 6 mg/kg on day 1 then 2 · 3 mg/kg/day)§ Yes B I [48]
Fluconazole (400 mg/day) ND C* I* [52,53]
Amphotericin B deoxycholate (0.5–1.0 mg/kg/day) Yes D IIt [44,54,56,57]
Micafungin (100 mg) Yes B II [49,50]
Anidulafungin ND NR No data
*Limited use since fluconazole has no mould activity. Application requires appropriate work-up to rule out mould disease.
NR, no recommendation; ND, no data available, §, dosis according to trial [48].
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the lack of antimould activity. Therefore, if fluconazole is
used, it remains essential to rule out a mould infection by
the Aspergillus galactomannan index (GMI) ELISA and chest
and sinus CT scan.
A consensus criteria defining pre-emptive (sometimes also
called ‘diagnostic driven’) treatment of fungal infections in can-
cer patients does not exist. The term ‘pre-emptive treatment’
is associated more with filamentous fungi infections than with
Candida-associated diseases. This approach is not driven by
persistent fever or neutropenia but rather by galactomannan
antigen detection in serum and/or BAL fluid or high-resolution
CT scan in high-risk patients [58]. The role 1,3-ß-D-glucan and
PCR testing for aspergillosis/candidiasis remains controversial
[59,60]. Whether or not any kind of infiltrate in the presence
of Aspergillus galactomannan should trigger antifungal therapy is
still debatable, although few experts would not add an antifun-
gal agent in all of these situations. Some experts wait for Asper-
gillus associated typical radiographic signs [halo, wedge shaped,
air crescent or cavity] before starting treatment [58]. Other
authors are more flexible [61,62]. Basically, no recommenda-
tion can be given at this point on the choice between the
empirical and pre-emptive approach.
No clinical trial has been performed to compare antifungal
drugs for this indication, and therefore, no recommendation
can be made. The main studies which tested the pre-emptive
approach used liposomal or deoxycholate formulation of
amphotericin B or voriconazole [61–63]. As treating pre-
emptively should mean treating at an early phase of disease,
drugs approved for the treatment of fungal diseases might be
effective or at least should be evaluated.
In summary, no data exist regarding whether or not Candida
diseases can be managed by pre-emptive anti-Candida therapy.
If Candida disease is the main concern and the patient is not on
azole prophylaxis, then fluconazole might be a good choice.
However, in contrast to the ICU setting, no trial has prospec-
tively assessed the role of Candida spp. colonization or 1,3-ß-
D-glucan in these patients [64]. 1,3-ß-D-glucan was assessed
previously in a meta-analysis by Lamoth et al. [65] The group
concluded that two consecutive positive antigen tests in
patients with haemato-oncological patients demonstrate a high
specificity, positive predictive value but a low sensitivity.
Therefore, the test needs to be combined with clinical and
radiological assessments and microbiological findings [65].
Mucosal oropharyngeal or oesophageal
candidiasis
Mucosal candidiasis does not play a significant role for
morbidity or mortality in haematological malignancies. The
occurrence of oropharyngeal or oesophageal candidiasis is
more inconvenient than threatening for the patient and usu-
ally easy to treat. For a rapid response, oral azoles, for
example fluconazole, are recommended (AI) [66]. Physicians
should keep in mind that azole-resistant Candida species can
be selected during therapy even without prolonged treat-
ment periods [67,68]. Other azoles can then be used [69–
74]. Topical polyenes treatment is recommended for mild
forms as in nonimmunocompromised patients [66,75–78].
Oral candidiasis with dysphagia and thoracic pain when
swallowing is suggestive of oesophageal involvement. In this
situation, topical treatment is not recommended (topical
polyene treatment for oesophagitis: DIII). Cases refractory
to fluconazole can be treated with any other azole if MIC
tests suggest susceptibility [70,71,79–82]. In the event of
severe or refractory disease, intravenous antifungals such as
an echinocandin or liposomal amphotericin B might be indi-
cated [83–90] (Table 5). It is essential to identify the species
causing candidiasis to ensure susceptibility to the chosen
agent [91]. This is a minimum requirement in immune-com-
promised patients, because resistance might have developed
and a mixed aetiology might be possible.
Targeted treatment of invasive candidiasis/
candidaemia
Treatment of invasive candidiasis or candidaemia should
always focus on the success of treatment with improved sur-
vival. Once the diagnosis of candidaemia is established, blood
cultures should be drawn on a daily basis until negativity for
at least two consecutive samples (B I). Treatment should at
least continue for 14 days after the last positive blood cul-
ture [92]. Individuals who have negative blood cultures for
more than 14 days but remain neutropenic at approximately
day 28 (or are not expected to recover from neutropenia)
should be evaluated for the resolution of clinical signs and
symptoms including exclusion of endocarditis and endoph-
thalmitis by appropriate examination. But defining an exact
and appropriate duration of therapy is still an issue of
debate.
It is recommended that for patients who are on prophy-
laxis that the class of drugs for antifungal treatment be chan-
ged (C III). In prospective trials, only a few neutropenic
patients were enrolled [93–97]. This consideration reduces
the level of our recommendation in comparison with inten-
sive care patients. Caspofungin and micafungin trials included
approximately 10% neutropenic patients [94–96]. The out-
come of these patients was also favourable, and therefore,
both agents received an AIIt recommendation. Anidulafungin
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on the other hand received a marginally weaker recommen-
dation (BIIt) because there were <3% neutropenic patients in
this trial [97]. The extensive usage of echinocandins could
trigger resistance against this class of antifungal agents in the
future because some areas in the world have demonstrated
an increase in C. parapsilosis which usually has higher MICs
compared with other Candida species [98,99]. Despite good
sensitivity results, first reports demonstrate caution on the
usage of echinocandins [100,101]. These are some of the
reasons for species discrimination and susceptibility testing
which are highly recommended in these settings.
Fluconazole, once considered gold standard in the treat-
ment of candidaemia received a weaker recommendation
despite positive outcomes in a number of trials [92,102].
These trials are considered out-dated, especially when con-
sidering the risk of the development of resistance. In recent
publications, previous fluconazole or triazole exposure and
gastrointestinal tract surgery are risk factors for fluconazole-
resistant candidaemia. In addition to invasive ventilation,
renal impairment, age >65 years and steroids and triazole
exposure are considered risk factors for death [6,103].
Therefore, fluconazole should only be considered as a step-
down treatment option in neutropenia when the Candida
species isolates demonstrate susceptibility to fluconazole.
Other azoles had only limited data and because of this,
itraconazole and posaconazole in particular, cannot be rec-
ommended for treatment [104]. On the other hand, more
data exist for voriconazole and it may be considered as an
option [105,106]. Despite equal outcome when compared to
micafungin, liposomal amphotericin B received only a BII rec-
ommendation due to its higher nephrotoxicity profile
[96,107]. Due to different toxicity profiles and weak data of
other lipid formulations of amphotericin B, a C grading for
the recommendation for treating invasive candidiasis or can-
didaemia is given [108–112]. Extensive nephrotoxicity, con-
secutive higher mortality and other unacceptable toxicity are
factors that make amphotericin B deoxycholate not recom-
mendable for treatment (DII) [30,31] (Table 6).
If patients were receiving fluconazole or liposomal ampho-
tericin B, a switch to an echinocandin might be desirable
(BIIt). Basically, there is no adequately powered randomized
trial for this situation neither for neutropenic patients nor
for stem cell transplant recipients but the identification of
the Candida species and susceptibility testing could be helpful
for making a decision (e.g. Candida krusei)(BIII).
In vitro and animal data of antifungal combinations seem to
improve the efficacy of antifungal treatment. In humans, espe-
cially neutropenic patients this outcome is not so clear-cut.
TABLE 5. Treatment of mucosal oropharyngeal or oesophageal candidiasis. Identification of Candida species would be
desirable
Diseases Intension Intervention SoR/QoE References
Oropharyngeal Eradication Nystatin suspension (non-neutropenic, mild presentation) CIIt [76,77]
Miconazole buccal BIIt [78]
Fluconazole AI [66,75]
Itraconazole solution BIIt [72–74]
Posaconazole AIIt [69,70]
Voriconazole BIII [71]
Echinocandins (anidulafungin, caspofungin) only in very severe and refractory cases BIII [84,149,150]
Liposomal amphotericin B as an option only in very severe and refractory cases CIII
Oesophageal Eradication Fluconazole AIIt [81,82,151–153]
Itraconazole BIIt [72,80,82]
Posaconazole AIIt [70]
Voriconazole AIII [71]
Topical treatment DIII
Echinocandins (anidulafungin, caspofungin and micafugnin) or liposomal amphotericin
B only in very severe and refractory cases
BIIt [84–90]
TABLE 6. Targeted treatment of invasive candidiasis/candidaemia in patients with malignancies, usually with neutropenia
Intention Intervention SoR QoE Comment References
Morbidity
reduction and
survival
improvement
Fluconazole C IIt Caution regarding resistance. Fluconazole should rather be considered as a
step-down treatment option
[92,93,102]
Itraconazole D III Only abstract in non-neutropenics [154]
Posaconazole D III One case report in a non-neutropenic [104]
Voriconazole C IIt Alternative agent due to better susceptibility data in comparison with
fluconazole but limited clinical data
[105,106]
Amphotericin B colloid dispersion C III Considerable nephrotoxicity [111,112]
Amphotericin B deoxycholate D IIt Unacceptable toxicity [30,31,44,93,94]
Amphotericin B lipid complex C IIa Considerable nephrotoxicity [108,110]
Anidulafungin B IIt <3% of the participants were neutropenic [97]
Caspofungin A IIt 10% of the participants were neutropenic [94,95]
Liposomal amphotericin B B IIt [96,107]
Micafungin A IIt 10% of the participants were neutropenic consider EMA warning [95,96]
CMI Ullmann et al. Guideline for the management of Candida diseases in haematological malignancies and HSCT 2012 59
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 7), 53–67
Only a few combinations have been studied without any
improved outcome. Combination of amphotericin B deoxych-
olate and 5-flucytosine is not recommended due to its toxicity
and erratic pharmacokinetics [113–115]. Efungumab and a lipid
formulation amphotericin B are also not recommended
because flaws in the design of the study hampered outcome
[116]. Efungumab is not an approved or marketed drug. The
combination of amphotericin B deoxycholate and fluconazole
was studied as a sequential therapy and did not demonstrate
any improvement to the comparators [105]. There was even
more toxicity in the amphotericin B group despite a median of
only 3 days of amphotericin B deoxycholate exposure.
Another trial assessed whether this combination was antago-
nistic [117]. Due to its similar outcome, this combination can
be considered an option (CIIt). Other combinations were not
studied but the expert opinion is that antifungal combinations
might be useful in severe deep-seated infections (e.g. abdomi-
nal infection, CNS and endocarditis, CIII).
Chronic disseminated candidiasis
Chronic disseminated candidiasis or hepato-splenic candidia-
sis is a very specific syndrome in patients with malignant dis-
eases. The disease usually occurs after the recovery of
neutrophils due to previous chemotherapy. The diagnosis of
chronic candidiasis is challenging when prior candidaemia has
not been documented. Imaging by ultrasound examination
demonstrates a weaker sensitivity in comparison with CT or
MRI [118–121]. Only one study could show a higher sensitiv-
ity utilizing MRI in comparison with CT [118]. But despite
adequate imaging techniques, the confirmation of the diagno-
sis by biopsy remains troublesome. Histology with culture
positivity is seldom. No comparator trials in regard to
morbidity improvement or survival advantage have been
performed or published. Antigen detection [e.g. mannan/anti-
mannan or 1,3-ß-D-glucan) are probably helpful, but data in
this situation are scarce [122]. Histology requires the use of
special staining (Gomori) and immunohistochemistry and
molecular-genetic workup is highly recommended.
In terms of treatment, only a few case series have been
published [96,123–126]. The experience of treatment is cur-
rently only anecdotal. Lipid formulations of amphotericin B
might be a good choice because of potential accumulation in
the reticulo-endothelial system [127]. Frequently, sequential
approaches are employed empirically, for example liposomal
amphotericin B followed by prolonged treatment of fluconaz-
ole. The disease has been recently considered to be an
inflammatory immune reconstitution syndrome [128]. There
are interesting publications that suggest the co-administration
of steroids at the beginning of treatment [129,130]. The
duration of antifungal treatment appears to be at least
8 weeks. Again the use of amphotericin B deoxycholate is
not encouraged (Table 7).
Biofilms and central venous catheters
Central venous catheters (CVC) play a major role in the
care of this patient population. Once inserted, the removal
or replacement might threaten the life of the patient because
of frequently experienced thrombocytopenia. Upon review
of the published data, a negative outcome during therapy by
not removing the central venous catheter early appears only
to occur in the situation where echinocandins were not used
[6,94–97,131,132]. In the recently published trials, where the
central venous catheter was retained, the outcome was simi-
lar but the numbers noted in those trials were low
[94,95,97]. Additionally, these trials demonstrated an equal
outcome in C. parapsilosis disease despite other publications
indicating higher MICs [133,134]. As C. parapsilosis is associ-
ated with catheter infections, removal would be desirable.
On the other hand, if catheter retention is clinical neces-
sary, treatment with an echinocandin remains an option.
Nevertheless, persistence of positive blood cultures for yeast
should prompt removal of a central venous catheter. Velasco
and Bigni [135] saw in their study by multivariate analysis
that comorbidities and neutropenia were independently asso-
ciated with mortality in adults and not CVC removal. In a
trial by Liu et al., early catheter removal is associated with
better survival. In this trial, the retention of the catheter,
high APACHE II score or thrombocytopenia was associated
with a higher mortality rate [131]. Nucci et al. [136] looked
especially on the outcome in terms of CVC removal and
reported no differences between the groups being given ca-
spofungin, micafungin or liposomal amphotericin B. But
TABLE 7. Treatment of chronic disseminated candidiasis
Intention Intervention Duration SoR/QoE Comments Reference
Eradication Fluconazole Reported duration minimum 3 months BIII [125,126] [125,126]
Other azoles (if susceptibility is expected) BIII Lacking data ND
Amphotericin B deoxycholate DIII Toxicity issues [30,31]
Lipid formulations of amphotericin B 8 weeks AIII Better exposure [96,124]
Defervesce Steroid therapy Until defervesce CIII [129,130]
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another work by Andes et al. [137] saw in review of seven
clinical trials that improved survival and greater clinical suc-
cess is associated with the use of an echinocandin and
removal of the CVC. A few in vitro studies indicate that ech-
inocandins penetrate Candida biofilm better than other anti-
fungal agents [138,139]. A more clinically challenging
question is how to handle other implanted hardware, for
example pacemaker, port-a-cath. Unless an association could
be provided, in cases with implanted hardware and with can-
didaemia, retention of the hardware is appropriate but no
published data are available. Unfortunately, no reliable symp-
tom or sign associated with hardware is available (Table 8).
Cytokines, colony-stimulating factors and
granulocyte infusions for the treatment of
invasive candidiasis or candidaemia
The question regarding the use of colony-stimulating factors
or cytokines in the treatment of invasive candidiasis or candi-
daemia remains unanswered. No controlled trials are avail-
able and only anecdotal data from small numbers of patients
exist. As persistent neutropenia is related to treatment fail-
ure, recovery from neutropenia substantiates the efficacy of
antifungal agents [140–142]. Therefore, the use of colony-
stimulating factors appears to be an option (C III). A recent
Cochrane review indicates no mortality differences for all
infections in patients suffering from neutropenia [143]. There
is only a weak recommendation for granulocyte infusions,
but the data are basically from children (CIII) [144–148]. This
treatment might be considered an option in desperate cases.
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Abstract
Mucosal candidiasis is frequent in immunocompromised HIV-infected highly active antiretroviral (HAART) naive patients or those who
have failed therapy. Mucosal candidiasis is a marker of progressive immune deficiency. Because of the frequently marked and prompt
immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the
HIV setting in Europe, although it has been evidenced as effective in the pre-HAART era. Fluconazole remains the first line of therapy
for both oropharyngeal candidiasis and oesophageal candidiasis and should be preferred to itraconazole oral solution (or capsules when
not available) due to fewer side effects. For patients who still present with fluconazole-refractory mucosal candidiasis, oral treatment
with any other azole should be preferred based on precise Candida species identification and susceptibility testing results in addition to
the optimization of HAART when feasible. For vaginal candidiasis, topical therapy is preferred.
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Introduction
Oropharyngeal (OPC) and oesophageal (OEC) candidiasis are
by far the most common fungal infections among patients with
human immunodeficiency virus (HIV) infection or acquired
immunodeficiency syndrome (AIDS) [1]. This guideline focuses
on patients with HIV infection or AIDS with Candida diseases.
The same grading system for the strength of recommendation
and its documented quality of evidence are used throughout of
this guideline as in the majority of the ESCMID Candida guide-
lines. The explanations and abbreviations used in this docu-
ment are given in Table 1 [85].
Before the era of highly active antiretroviral therapy (HA-
ART), OPC occurred in as many as 90% of patients, at some
point during the course of HIV infection [1]. Although the
incidence of mucosal Candida colonization and infection has
been dramatically reduced with the introduction of HAART,
it remains a common opportunistic infection in those HIV-
infected patients without access to HAART or those in
whom antiviral therapy is started late.
Oesophageal candidiasis was the leading opportunistic
infection before the HAART era [2] and remains the second
AIDS-defining illness in Europe [3]. In addition, mucosal can-
didiasis is still problematic in patients with poor adherence
to treatment and/or multiple virological–immunological fail-
ures. The occurrence of OPC and OEC are indicators of
profound immune suppression, and these syndromes are
most often observed in patients with CD4+ counts
<200 cells/lL with OEC being found in a more advanced
stage of AIDS than OPC [1]. OPC and OEC are more diffi-
cult infections to treat in the context of HIV infection com-
pared with other immunocompromised patients [4].
Candida albicans is the most prominent pathogen. This
organism can be found in the oral cavity of up to two-thirds
of healthy individuals [5]. No particular strains have a pre-
ponderance to cause mucosal candidiasis. Acquired fluconaz-
ole (or pan triazole) resistance is related to previous
exposure to fluconazole (or other triazoles), particularly if
repeated and prolonged exposure in the context of profound
immunosuppression [6–8]. Fluconazole resistance is associ-
ated with the cumulative exposure to fluconazole; patients
failing fluconazole have received larger cumulative dosages of
fluconazole (mean value, 8.7 g) [9]. The transmission of iso-
lates (including those resistant to fluconazole) has been doc-
umented between HIV-infected partners [10]. Therefore,
examination of partners is recommended.
In this setting, C. albicans resistance has also been accom-
panied by an emergence of non-albicans Candida species with
intrinsic reduced azole susceptibility in the oral cavity (partic-
ularly C. krusei and C. glabrata [11]) and in the vagina [12].
C. glabrata may cause refractory mucosal candidiasis, particu-
larly in patients with advanced immunosuppression [13].
Candida dubliniensis was first associated with OPC in HIV-
infected patients [14]. The introduction of HAART with immu-
nological reconstitution has led to a dramatic decline in the
incidence of refractory disease and of infections caused by
resistant Candida isolates. Barchiesi et al. [11] found that 93%
of Candida collected from oral cavities among 102 HAART-
treated patients remained susceptible to fluconazole, despite
many of these patients receiving repeated courses of triazoles.
Clinical manifestations
Three clinical patterns of OPC have been described: ery-
thematous, pseudo-membranous and angular cheilitis. OPC
can occur at any stage of HIV infection (primary infection,
chronic asymptomatic phase and AIDS), but erythematous
(erythematous patches without white plaques visible on the
anterior or posterior upper palate or diffusely on the ton-
gue) and pseudomembranous (creamy white, plaque-like
lesions of the buccal or oropharyngeal mucosa or tongue
surface) forms are predictive of progressive immunodefi-
ciency [15].
Oesophageal symptoms include retrosternal burning pain,
altered taste and odynophagia. Endoscopic examination
reveals whitish plaques similar to those observed with OPC
that might progress to superficial ulceration of the OEC
mucosa, with central or surface whitish exudates.
As relapse of OPC and OEC is common, it is often associ-
ated with recurrence of intense pain that contributes to
weight loss because of poor nutrition.
TABLE 1. Strength of the ESCMID recommendation and
quality of evidence
Strength of a recommendation
Grade A ESCMID strongly supports a recommendation for use
Grade B ESCMID moderately supports a recommendation for use
Grade C ESCMID marginally supports a recommendation for use
Grade D ESCMID supports a recommendation against use
Quality of evidence
Level I Evidence from at least one properly designed randomized,
controlled trial
Level II* Evidence from at least one well-designed clinical trial,
without randomization; from cohort or case–controlled
analytic studies (preferably from >1 centre); from multiple
time series; or from dramatic results of uncontrolled
experiments
Level III Evidence from opinions of respected authorities, based on
clinical experience, descriptive case studies
*: Added index:
r: meta-analysis (or systematic review of randomized control trials).
t: transferred evidence , that is, results from different patients’ cohorts, or simi-
lar immune-status situation.
h: comparator group: historical control.
u: uncontrolled trials.
a: published abstract (presented at an international symposium or meeting).
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In contrast, vulvovaginal candidiasis is common among
healthy adult women and is often unrelated to HIV status.
Consequently, recurrent vulvovaginal candidiasis alone can-
not be ascribed to advanced HIV disease.
Candida vulvovaginitis may be mild to moderate in severity
and sporadic (similar to normal hosts). This syndrome is
characterized by a white adherent vaginal discharge that is
associated with burning and itching. In patients with advanced
immunosuppression, episodes may be more severe and more
frequently recurrent. Compared with OPC, vaginal candidia-
sis is frequently more responsive to triazole therapy.
Diagnosis of oropharyngeal candidiasis and
oesophagitis
A diagnosis of OPC is usually made on clinical grounds.
Lesions can be readily scraped with a tongue depressor or
other instrument to obtain samples for a microbiological
diagnosis. Fungal selective media should be used to avoid
overgrowth by colonizing bacteria [16]. Identification to spe-
cies level and susceptibility testing are recommended in
recurrent cases of OPC and for patients repeatedly exposed
to fluconazole (and/or other triazoles). If an upper endos-
copy is performed, a biopsy may enable infection to be dis-
tinguished from colonization or other mucosal diseases [16].
The diagnosis of OEC requires endoscopic visualization of
lesions with histopathologic demonstration of characteristic
Candida yeast forms in tissue and culture confirmation of the
presence of Candida species.
The diagnosis of vulvovaginal candidiasis is made with a
combination of characteristic clinical appearances combined
with standard microbiological investigations. The detection of
serum biomarkers such as mannan/antimannan or ß-D-glucan
is not required to confirm a diagnosis of mucosal candidiasis.
Primary prophylaxis of mucosal candidiasis
Despite the demonstrated efficacy of fluconazole, primary
antifungal prophylaxis for the prevention of OPC and OEC is
not recommended in Europe (DI). Fluconazole (200 mg/day)
is superior to clotrimazole troches in a large randomized
multicentric unblinded trial for the prevention of both OEC
and OPC with a greatest benefit in patients with less than
50 CD4/mm3 [17]. In addition, in a double-blind trial, Havlir
et al. [18] observed double the rate of OPC among patients
receiving 400 mg fluconazole weekly compared with those
treated with 200 mg daily. Fluconazole 200 mg/week in a
randomized double-blind placebo-controlled trial involving
HIV-infected women prevented OPC and vaginal candidiasis
but not OEC [19]. In a retrospective study, Manfredi et al.
[20] demonstrated that fluconazole 100 mg/day every
3 weeks prevented the occurrence of OEC vs. no therapy.
Finally, other triazoles such as itraconazole are more effec-
tive than placebo in the prevention of superficial Candida sp.
infections [21] (Table 2).
While OPC may be associated with significant morbidity,
the disadvantages of primary prophylaxis include the potential
for drug–drug interactions between triazoles and HAART, the
development of fluconazole resistance and/or cross-resistance
to azoles, the availability of effective antifungal therapy for
OPC and the cost and potential toxicity of triazole antifungal
agents. Thus, the best prophylaxis of both OPC and OEC is
the appropriate compliance to HAART (AII).
Treatment of first OPC episodes due to
triazole susceptible isolates
More than 20 years after its introduction, fluconazole
remains the leading antifungal drug that is used for OPC.
Fluconazole is fungistatic against Candida spp. with an oral
bioavailability of over 80%, which is not influenced by con-
comitant food intake or gastric pH. Penetration into saliva is
excellent. Tablets, oral solution and intravenous formulation
can all be used to treat OPC. Because of hepatic metabolism
via the CYP450 enzyme complex, many drug interactions
with fluconazole have been described. Fluconazole is well
tolerated within the recommended range of doses for muco-
sal candidiasis. Side effects increasingly occur with doses in
excess of 400 mg per day, which are not usually necessary
for treatment of mucosal candidiasis [22]. Finally, EUCAST
and CLSI susceptibility breakpoints have been defined for
fluconazole and C. albicans, C. parapsilosis and C. tropicalis: sus-
ceptible, MIC £2 mg/L; and resistant, MIC >4 mg/L according
to both EUCAST and CLSI (http://www.eucast.org).
Fluconazole at a dosage of 100 mg/day for 7–14 days is
recommended for the first-line agent for the treatment of
OPC for adults [23–28] and children (AI) [29,30] (Table 2).
The majority of patients with OPC that is caused by fluco-
nazole-susceptible isolates will respond to therapy within
72 h. Approximately 80% of patients are cured, and a further
10% experience significant improvement in their symptoms
[31]. OPC is a mandatory indication of HAART’s initiation
(AII). No long-term suppressive triazole therapy should be
used (DIII).
Potential alternatives to fluconazole include (i) miconazole
as a mucoadhesive tablet 10 or 50 mg once daily for
7–14 days (approved in Europe since 2008 in its 50 mg for-
70 Clinical Microbiology and Infection, Volume 18 Supplement 7, December 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 7), 68–77
mulation) (BI). Miconazole was studied in a randomized trial
vs. ketoconazole (similar efficacy but reportedly had more
episodes of vomiting in patients on ketoconazole) and in a
large phase III double-blind double dummy trial vs. clotrima-
zole (similar efficacy and acceptable tolerability), but not to
the reference drug fluconazole [32–34]; (ii) itraconazole oral
solution. Itraconazole solution for 7–14 days (100 or
200 mg/day) is equivalent to fluconazole for 14 days [35,36]
(BI). Itraconazole solution may be beneficial even without
the attainment of detectable serum levels because of its
direct effect if swished in mouth for few seconds before
swallowing [37]. Itraconazole solution is associated with a
30% increase in itraconazole absorption in comparison with
the capsule formulation [38] and with a comparable rate of
side effects compared with fluconazole [35,36] for OPC.
Itraconazole has a higher incidence of erratic oral bioavail-
ability and drug–drug interactions compared with fluconaz-
ole. The use of itraconazole may be complicated by
cross-resistance to fluconazole. Indeed, in one study, 30% of
fluconazole-resistant isolates were cross-resistant to itraco-
nazole, and itraconazole solution has been shown effective
during OPC in this context against itraconazole susceptible
isolates [39]; (iii) voriconazole has not been studied for
fluconazole-susceptible OPC; (iv) posaconazole (200 mg on
day 1 then 100 mg daily) is also an alternative to fluconazole
[40]. Posaconazole is better tolerated and has fewer interac-
tions compared with both itraconazole and voriconazole, but
has a broad spectrum of activity for treating initial episodes
of OPC and is considered an option for therapy in cases
with fluconazole-resistant Candida sp. (CI).
Topical agents (e.g. amphotericin B lozenges or nystatin)
should not be used for the treatment of OPC because of
suboptimal tolerability (bitter taste, gastro-intestinal side
effects, frequent dosing) and lower efficacy [27] (DI). Fur-
thermore, a recommendation for clotrimazole was not con-
sidered because this agent is not available in Europe. While
clotrimazole is effective, it is less efficacious and associated
with a higher rate of relapses in comparison with fluconazole
at least in some studies [25,26,28]. Finally, acquired
resistance to clotrimazole has been documented in Candida
isolates in OPC [41].
Ketoconazole is efficacious in comparison with fluconazole
and itraconazole but its use is limited by hepatotoxicity,
drug–drug interactions, limited oral bioavailability in the set-
TABLE 2. Recommendations made for patients with HIV infection or AIDS and Candida disease
Intention Intervention SoR QoE Reference/Commentary
Primary prophylaxis of mucosal
candidiasis (OPC/OEC)
Primary antifungal prophylaxis of OPC/OEC D I [17][19][18][20][21] although effective [interactions/
acute therapy effective/induction of resistance/no
mortality related to OPC/cost)
Best prophylaxis is appropriate compliance
to HAART
A II [80][81][82][83][84]
Treatment of first episodes of
oropharyngeal candidiasis
(OPC) due to azole
susceptible isolates
HAART should be initiated A II [80][81][82][83][84]
Fluconazole (100 mg/day in adults, at least
7 days)
A I [23][11][26,27][25][28][29][30]
Miconazole mucoadhesive tablet B I [32][33]
Itraconazole oral solution B I [35][36]
Posaconazole (100 mg/day) C I [4]
Voriconazole – – No published data
Topical agents D I [27][29]
Ketoconazole D I [23][11][45][42]
Itraconazole capsules D III Because of poor absorption [39]
Echinocandins and any amphotericin B
formulation
D III No published data
Chronic suppressive therapy D III No published data
Treatment of oesophageal
candidiasis
Start treatment without endoscopy A III In case of oesophageal symptoms and OPC,
endoscopy is not indicated.
Oral fluconazole (200 mg/day for
14–21 days) (or i.v. for those who cannot
swallow)
A I [23][48][46][47]
Itraconazole solution B I [49][46][47]
Echinocandins can be used in patients who
cannot swallow but not better than
Fluconazole
C I [55][56][57][53][54]
Higher relapse rate with caspofungin and
anidulafungin vs fluconazole
Ketoconazole D I [48][42]
Any i.v. amphotericin B formulation D III No role for the management of OEC due to azole
susceptible isolates
Local treatments D III Less effective than fluconazole
Treatment of refractory
OPC/OEC
Itraconazole oral solution (‡200 mg/day) A II [64][63][65]
Posaconazole (400 mg twice daily) A II [66][67]
Voriconazole (200 mg twice daily) C II [68]
Any echinocandin A II [70][71][72]
All echinocandins may be considered equivalent here
Any amphotericin B formulation C II No published data
Suppressive therapy Fluconazole 100–200 mg 3·/week A I [75][76][77][78][19][18][9][79]
HAART, highly active antiretroviral; OEC, oesophageal.
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ting of hypochlorhydria and appears to select for triazole
cross-resistance [11,23,42–45]. Ketoconazole is thus not rec-
ommended for the management of OPC (DI).
Echinocandins should not be considered for OPC episodes
caused by isolates that are susceptible to triazoles due to their
parenteral availability and cost in comparison with fluconazole
(DIII). Finally, any intravenous formulation of amphotericin B is
also not recommended for the management of OPC due to
numerous adverse events and associated nephrotoxicity (DIII).
Treatment of oesophageal candidiasis due
to triazole susceptible isolates
Antifungal therapy for OEC should be initiated without endos-
copy, especially if patients have signs and symptoms of OEC and
oropharyngeal lesions are suggestive of mucosal candidiasis
(AIII). Topical agents are not effective enough and should be
avoided (DIII). Oral fluconazole (200 mg/day for 14–21 days) is
the treatment of choice [46–48] (AI). Intravenous formulation
can be used in case of severe oesophagitis (Table 2).
Itraconazole (oral solution) is an alternative agent that has
been shown to be as effective clinically and mycologically as
fluconazole, but endoscopic cure was found less frequently
especially during short-term therapy in the itraconazole arm
[46,47,49] (BI). Itraconazole capsules are not recommended
because of limited oral bioavailability (DII) The addition of
flucytosine to itraconazole is not superior to fluconazole and
is not recommended [50] (DI).
Voriconazole 200 mg twice daily for 14–21 day is equally
as efficacious as fluconazole, but associated with a higher
incidence of adverse events [51] and more potential drug–
drug interactions, visual abnormalities and phototoxicity in
ambulatory patients (BI).
Oral flucytosine alone was tested against fluconazole but
was proven less effective [52], in addition to potential side
effects (DI). Oral ketoconazole was tested against fluconaz-
ole in a large double-blind trial, and endoscopic and clinical
cure rates were inferior in the ketoconazole arm [48].
Ketoconazole was also tested in a small trial against itrac-
onazole with a higher efficacy than itraconazole [42] (DI).
Finally among azoles, posaconazole has not been specifically
studied in the context of primary treatment of oesophagitis
in azole susceptible isolates and should be reserved for
refractory or resistant disease.
The echinocandins have been evaluated for the treatment of
AIDS-associated OEC mostly in comparison with fluconazole.
However, these antifungals are only available parenterally
and are much less convenient to use than oral azoles (CI).
Caspofungin is associated with similar response rates and
tolerability compared with fluconazole although higher
relapse rates were observed with caspofungin [53]. Caspo-
fungin has been shown superior (74–91% efficacy) to ampho-
tericin B (63%) in one study [54]. Micafungin (50–150 mg/
day) produces a dose-dependent response rate in OEC [55].
The use of 150 mg/day regimen was comparable both in
terms of efficacy, relapse rate and tolerance compared with
fluconazole (200 mg/day) in a large double-blind study [56].
The currently licensed dosage is 150 mg/day. Similarly, anidu-
lafungin [100 mg/day after loading dose] produces compara-
ble response rates to fluconazole, but the rate of relapse 2
weeks after cessation of therapy was higher [57].
Intravenous formulations of amphotericin play no role for
the management of OEC due to azole susceptible Candida
isolates (DII).
Management of refractory OPC and or
OEC
Refractory OPC or OEC is defined by symptoms that persist
after more than 14 days of fluconazole ‡200 mg/day. This
syndrome is reported in approximately 5% of HIV-infected
patients and typically in those with CD4+ counts <50 cells/
lL who have received multiple and prolonged courses of an-
tifungals/triazole agents for a high number of OPC episodes
[6–8]. The clinical impact of refractory mucosal candidiasis
has been well documented [58]. In this situation, careful
identification to species level and in vitro susceptibility testing
to fluconazole and other triazoles are mandatory. Detection
of resistance based on in vitro established breakpoints is
indeed of major importance as mucosal candidiasis is one of
the clinical settings where the correlation between in vitro
results and in vivo outcome has been established [59,60].
Any use of a topical antifungal agent such as amphotericin
B [61] should be avoided because of low efficacy rates (DIII).
The use of fluconazole at a higher daily dosage may be bene-
ficial at least transiently, particularly with the suspension,
which provides increased salivary concentrations [62] (BIII).
Itraconazole solution (up to 600 mg/day) is an alternative
and is associated with a 55–75% response rate, but relapses
occur subsequently [63–65] (AII).
Posaconazole oral suspension [400 mg twice daily (i.e. a
higher dosage than that used for nonrefractory mucosal
infections) for 28–90 days] can also be used and is efficacious
in up to 86% of patients with fluconazole and/or itraconazole
refractory oropharyngeal and/or OEC candidiasis. It has been
approved by EMA in such context. In addition, the use of po-
saconazole is well tolerated up to 90 days of therapy, but
relapses do also occur during the follow-up [66,67] (AII).
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Voriconazole appears to be active against fluconazole-
resistant Candida isolates isolated from mucosal infections
[68] although cross-resistance has also been demonstrated
[69]. Voriconazole has been shown effective in a limited
number of refractory OEC cases [68] (CII). If prolonged
azole therapy is anticipated, periodic monitoring of liver
enzymes should be considered (BIII).
Caspofungin can be used for HIV-infected patients with
clinically fluconazole-refractory OEC or microbiologically
resistant disease. A favourable response is obtained in 83%
and 79% of cases, respectively [70]. Caspofungin can also be
used for patients with refractory OPC/OEC who have expe-
rienced failure or intolerance to polyenes [71] (AII). Anidula-
fungin can also be used in this setting. An open-label clinical
trial also studied anidulafungin in fluconazole-resistant OPC/
OEC in 19 patients with a 95% successful clinical response,
including 11/12 patients with OEC who had endoscopic cure
(92%). Tolerance was acceptable [72] (AII). In addition,
azole-refractory mucosal candidiasis can also be treated with
micafungin 150 mg/day although it has not been specifically
studied in that setting (AII).
Amphotericin B deoxycholate, amphotericin B lipid com-
plex and liposomal amphotericin B may also be effective in
such setting, but their toxicity profiles should receive consid-
erable attention (CII). Preliminary studies have suggested a
potential benefit of adjunctive GM-CSF therapy [73] (CII).
Finally, any perspective of a new HAART regimen appears
crucial in this context [74] (AIII).
Vulvovaginal candidiasis
Vulvovaginal candidiasis usually responds readily to topical
agents (AII). Short-course oral azole therapy although effec-
tive should be avoided (fluconazole (DII), itraconazole oral
solution (DII)). In case of multiple episodes, oral fluconazole
(150 mg/week) should be used to prevent recurrences as
evidenced outside the HIV setting (AI).
Prevention of recurrences
Maintenance therapy or secondary prophylaxis to prevent
recurrences is usually not recommended (DIII). However,
when relapses are frequent and/or severe, long-term oral
triazole use may be considered providing cost and toxicity
are acceptable. Fluconazole maintenance therapy has been
well documented as effective in several randomized studies
performed during the pre-HAART era. It should be
reserved for patients with relapsing OPC/OEC caused by a
fluconazole-susceptible isolate after HAART optimization
(or failing HAART therapy). The range of dosages is large:
50–200 mg/day or 150–400 mg/week] (BI) [9,18,19,75–78]
(Table 2).
Maintenance therapy with fluconazole 100–200 mg 3·/
week should be considered for the case of recurrent infec-
tions to prevent further relapse (AI), but daily administration
of fluconazole should be favoured (BI). A more recent ran-
domized clinical trial has documented that fluconazole
(200 mg three times a week) vs. episodic treatment of recur-
rences therapy was significantly associated with fewer cases
of OPC or OEC and fewer invasive fungal infections, but not
with improved survival in HIV patients with CD4+ count
<150 cells/lL. In the latter study, no difference in the rate of
fluconazole-refractory candidiasis was noticed provided that
patients received HAART [79]. Oral posaconazole 400 mg
twice daily can be proposed in case of relapsing OEC due to
fluconazole-resistant Candida isolates (BII). Triazole therapy
is precluded in pregnancy (AIII). Clinical experience, but no
specific study, suggests that maintenance therapy is not
required in the context of immune reconstitution to CD4-
positive cells >200/lL (AIII).
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